<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS189149</article-id><article-id pub-id-type="doi">10.1101/2023.10.03.560722</article-id><article-id pub-id-type="archive">PPR735931</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Drug Discovery in Low Data Regimes: Leveraging a Computational Pipeline for the Discovery of Novel SARS-CoV-2 Nsp14-MTase Inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nigam</surname><given-names>AkshatKumar</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hurley</surname><given-names>Matthew F. D.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Fengling</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>KonkoĬová</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Klíma</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Trylčová</surname><given-names>Jana</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Pollice</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref><xref ref-type="fn" rid="FN1">8</xref></contrib><contrib contrib-type="author"><name><surname>Çinaroğlu</surname><given-names>Süleyman Selim</given-names></name><xref ref-type="aff" rid="A8">9</xref></contrib><contrib contrib-type="author"><name><surname>Levin-Konigsberg</surname><given-names>Roni</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Handjaya</surname><given-names>Jasemine</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Schapira</surname><given-names>Matthieu</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A9">10</xref></contrib><contrib contrib-type="author"><name><surname>Chau</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Perveen</surname><given-names>Sumera</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ng</surname><given-names>Ho-Leung</given-names></name><xref ref-type="aff" rid="A10">11</xref></contrib><contrib contrib-type="author"><name><surname>Kaniskan</surname><given-names>H. Ümit</given-names></name><xref ref-type="aff" rid="A11">12</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Yulin</given-names></name><xref ref-type="aff" rid="A11">12</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Sukrit</given-names></name><xref ref-type="aff" rid="A12">13</xref></contrib><contrib contrib-type="author"><name><surname>Gorgulla</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="A13">14</xref><xref ref-type="aff" rid="A14">15</xref><xref ref-type="aff" rid="A15">16</xref></contrib><contrib contrib-type="author"><name><surname>Kundaje</surname><given-names>Anshul</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="A11">12</xref></contrib><contrib contrib-type="author"><name><surname>Voelz</surname><given-names>Vincent A.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Weber</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nencka</surname><given-names>Radim</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Boura</surname><given-names>Evzen</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Vedadi</surname><given-names>Masoud</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A9">10</xref><xref ref-type="aff" rid="A16">17</xref><xref ref-type="aff" rid="A17">18</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Aspuru-Guzik</surname><given-names>Alán</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref><xref ref-type="aff" rid="A18">19</xref><xref ref-type="aff" rid="A19">20</xref><xref ref-type="aff" rid="A20">21</xref><xref ref-type="aff" rid="A21">22</xref><xref ref-type="aff" rid="A22">23</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Computer Science, Stanford University</aff><aff id="A2"><label>2</label>Department of Genetics, Stanford University</aff><aff id="A3"><label>3</label>Department of Chemistry, Temple University, Philadelphia, PA 19122, USA</aff><aff id="A4"><label>4</label>Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada</aff><aff id="A5"><label>5</label>Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic</aff><aff id="A6"><label>6</label>Chemical Physics Theory Group, Department of Chemistry, University of Toronto, 80 St. George St, Toronto, Ontario M5S 3H6, Canada</aff><aff id="A7"><label>7</label>Department of Computer Science, University of Toronto, 40 St. George St, Toronto, Ontario M5S 2E4, Canada</aff><aff id="A8"><label>9</label>Structural Bioinformatics and Computational Biochemistry, Department of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK</aff><aff id="A9"><label>10</label>Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada</aff><aff id="A10"><label>11</label>Department of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS 66506, USA</aff><aff id="A11"><label>12</label>Department of Pharmacological Sciences and Oncological Sciences, Mount Sinai Center for Therapeutics Discovery, Tisch Cancer Institute, Ichan School of Medicine at Mount Sinai, New York, NY, USA</aff><aff id="A12"><label>13</label>Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center</aff><aff id="A13"><label>14</label>St. Jude Children’s Research Hospital, Department of Structural Biology, Memphis, TN, USA</aff><aff id="A14"><label>15</label>Department of Physics, Faculty of Arts and Sciences, Harvard University, Cambridge, USA</aff><aff id="A15"><label>16</label>Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA</aff><aff id="A16"><label>17</label>QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA</aff><aff id="A17"><label>18</label>Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada</aff><aff id="A18"><label>19</label>Department of Chemical Engineering &amp; Applied Chemistry, University of Toronto, Canada</aff><aff id="A19"><label>20</label>Department of Materials Science &amp; Engineering, University of Toronto, Canada</aff><aff id="A20"><label>21</label>Vector Institute for Artificial Intelligence, Toronto, Canada</aff><aff id="A21"><label>22</label>Canadian Institute for Advanced Research (CIFAR), Toronto, ON, Canada</aff><aff id="A22"><label>23</label>Acceleration Consortium, University of Toronto, Toronto, ON, Canada</aff><author-notes><corresp id="CR1"><label>*</label>Correspondence to: <email>m.vedadi@utoronto.ca</email>, <email>aspuru@utoronto.ca</email>
</corresp><fn id="FN1" fn-type="current-aff"><label>8</label><p id="P1">Current affiliation: Stratingh Institute for Chemistry, University of Groningen, The Netherlands</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>06</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>04</day><month>10</month><year>2023</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P2">The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to significant global morbidity and mortality. A crucial viral protein, the non-structural protein 14 (nsp14), catalyzes the methylation of viral RNA and plays a critical role in viral genome replication and transcription. Due to the low mutation rate in the nsp region among various SARS-CoV-2 variants, nsp14 has emerged as a promising therapeutic target. However, discovering potential inhibitors remains a challenge. In this work, we introduce a computational pipeline for the rapid and efficient identification of potential nsp14 inhibitors by leveraging virtual screening and the NCI open compound collection, which contains 250,000 freely available molecules for researchers worldwide. The introduced pipeline provides a cost-effective and efficient approach for early-stage drug discovery by allowing researchers to evaluate promising molecules without incurring synthesis expenses. Our pipeline successfully identified seven promising candidates after experimentally validating only 40 compounds. Notably, we discovered NSC620333, a compound that exhibits a strong binding affinity to nsp14 with a dissociation constant of 427 ± 84 nM. In addition, we gained new insights into the structure and function of this protein through molecular dynamics simulations. We identified new conformational states of the protein and determined that residues Phe367, Tyr368, and Gln354 within the binding pocket serve as stabilizing residues for novel ligand interactions. We also found that metal coordination complexes are crucial for the overall function of the binding pocket. Lastly, we present the solved crystal structure of the nsp14-MTase complexed with SS148 (PDB:8BWU), a potent inhibitor of methyltransferase activity at the nanomolar level (IC<sub>50</sub> value of 70 ± 6 nM). Our computational pipeline accurately predicted the binding pose of SS148, demonstrating its effectiveness and potential in accelerating drug discovery efforts against SARS-CoV-2 and other emerging viruses.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><label>I</label><title>Introduction</title><p id="P3">The COVID-19 pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has had a profound impact on global health, economies, and daily life. SARS-CoV-2 is a single-stranded, positive-sense RNA virus belonging to lineage B of the genus Beta-coronavirus in the Coronaviridae family [<xref ref-type="bibr" rid="R1">1</xref>]. Since its emergence in December 2019, it has led to a staggering number of infections and deaths world-wide, overwhelming healthcare systems and prompting unprecedented public health measures [<xref ref-type="bibr" rid="R2">2</xref>]. While the development of vaccines has been a significant step in combating the virus, the continued emergence of new variants highlights the ongoing need for effective antiviral treatments. Such treatments can play a crucial role in reducing the severity and impact of infections and informing future pandemic policy decisions [<xref ref-type="bibr" rid="R3">3</xref>]. The SARS-CoV-2 genome is notably large, containing nearly 30,000 base pairs and encoding 16 nonstructural proteins (nsps) that play vital roles in viral replication and transcription [<xref ref-type="bibr" rid="R4">4</xref>]. Because of this, nsps represent potential targets for therapeutics, and the availability of their structural data has facilitated the rapid development of antivirals [<xref ref-type="bibr" rid="R5">5</xref>]. One such target is non-structural protein 14 (nsp14), which has dual functions as an exonuclease (ExoN) and a methyltransferase (MTase). The ExoN function ensures replication fidelity through 3’-5’ proofreading, while the MTase function catalyzes N7-methylation of the guanosine triphosphate cap of the viral RNA, which is crucial for its stability and function [<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>]. Due to its low mutation rate among different SARS-CoV-2 variants when compared to other viral proteins such as the spike protein [<xref ref-type="bibr" rid="R8">8</xref>], nsp14 is hypothesized to be essential for the function of the virus, and therefore it has emerged as a promising therapeutic target. This persistence increases the likelihood that inhibitors targeting nsp14 will remain effective against a broader range of evolving viral strains. Additionally, the amino acid sequence of SARS-CoV-2 nsp14 shows high homology with nsp14 from other coronaviruses, including SARS-CoV, MERS-CoV, and common human coronaviruses such as OC43, HKU1, 229E, and NL63 [<xref ref-type="bibr" rid="R8">8</xref>]. This sequence conservation suggests that inhibitors targeting nsp14 in SARS-CoV-2 could potentially also inhibit nsp14 MTase activity in other coronaviruses, which may have implications for the development of broad-spectrum antiviral drugs [<xref ref-type="bibr" rid="R9">9</xref>].</p><p id="P4">In this study, we developed a computational pipeline for rapid and efficient identification of potential nsp14 in-hibitors. By leveraging virtual screening at various levels of accuracy and the NCI open compound collection [<xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R11">11</xref>]—a database comprising 250,000 freely accessible molecules for researchers globally, we evaluated promising molecules without the expense and time typically associated with synthesis. This cost-effective and efficient strategy proves particularly valuable for early-stage hit identification, in cases where resources are constrained and time is of the essence. We utilized molecular docking [<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R13">13</xref>] and Molecular Mechanics Generalized Born Surface Area (MM/GBSA) calculations [<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R15">15</xref>] to gauge the strength of interaction between potential inhibitors and nsp14. Through these computational methodologies, we successfully identified a novel inhibitor for nsp14, with activity in the micromolar range, labelled NSC620333 (IC<sub>50</sub> value of 5.3 ± 1.0 <italic>μM</italic>), which was confirmed by orthogonal in vitro and in vivo assays. This inhibitor was unearthed through computational screening of the NCI open compound collection, with only the top 40 compounds undergoing experimental testing, highlighting the efficiency of our pipeline. Furthermore, to deepen our understanding of the protein structure and function, we conducted molecular dynamics (MD) simulations [<xref ref-type="bibr" rid="R16">16</xref>–<xref ref-type="bibr" rid="R18">18</xref>] exceeding 5 microseconds. These simulations unveiled previously unknown conformational states of nsp14, offering valuable insights into its overall function. Within the MTase lateral cavity, we identified flexible residues—specifically Phe367, Tyr368, and Gln354—that form stabilizing interactions with potential ligands. Our simulations also revealed that the two alpha-helices of the MTase domain undergo a significant shift/bend, corresponding to the opening and closing of the lateral cavity. Importantly, these conformational shifts were not observed in the absence of metal coordination complexes, emphasizing their crucial role in stabilizing interactions. Our MD simulations also shed light on the interaction of nsp14 with nsp10, a key process in viral replication and transcription. Nsp10 has been demonstrated to stimulate the ExoN and MTase activities of nsp14, making it a critical cofactor for the functionality of the protein [<xref ref-type="bibr" rid="R19">19</xref>]. In summary, our research showcases an advanced computational pipeline, built upon the robust capabilities of VirtualFlow 2.0 [<xref ref-type="bibr" rid="R20">20</xref>], specifically the VirtualFlow Unity (VFU) module. This component not only accommodates a wide spectrum of docking programs, callable through a Python pipeline, but also allows scoring at diverse levels of precision, thereby facilitating the rapid and proficient detection of prospective nsp14 inhibitors. This is achieved by integrating virtual screening strategies and harnessing the expansive NCI open compound collection. Through this methodology, we discovered NSC620333, a compound exhibiting strong binding affinity to nsp14, and gained fresh insights into the structure and function of the protein. Furthermore, we report the crystal structure of SS148, a potent inhibitor (IC<sub>50</sub> value of 70 ± 6 nM) of methyltransferase activity, in complex with the nsp14-MTase domain [<xref ref-type="bibr" rid="R21">21</xref>, <xref ref-type="bibr" rid="R22">22</xref>]. Our pipeline accurately predicted the binding pose of SS148, demonstrating its efficacy and potential for expediting drug discovery efforts against SARS-CoV-2 and other emerging viruses. By targeting the nsp14 protein, we aspire to contribute to the development of effective antiviral therapies against SARS-CoV-2 and its variants, and other coronaviruses as well. Our computational pipeline offers a cost-effective and efficient strategy for early-stage drug discovery, potentially providing significant assistance to researchers battling the rapidly mutating virus responsible for COVID-19 and aiding in the response to future disease outbreaks.</p></sec><sec id="S2" sec-type="results"><label>II</label><title>Results</title><sec id="S3"><label>A</label><title>Employing Molecular Docking for identifying nsp14 inhibitors</title><p id="P5">The widespread use of structure-based drug discovery techniques has proven instrumental in the search for small molecules that can specifically target macromolecules. [<xref ref-type="bibr" rid="R23">23</xref>] The efficacy of molecular docking and free energy simulation methods is particularly noteworthy in assessing the binding strength between proteins and ligands. [<xref ref-type="bibr" rid="R24">24</xref>] These methods enabled us to identify and prioritize the most promising candidates, thereby facilitating subsequent experimental testing. Our aim was to identify inhibitors of the SARS-CoV-2 nsp14 MTase activity. To achieve this, we performed a computational screening of the Developmental Therapeutics Program (DTP) Open Compound Collection. [<xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R11">11</xref>] Comprising approximately 250,000 molecules synthesized and tested for potential efficacy against cancer and acquired immunodeficiency syndrome, this collection offers a considerable resource for researchers. Importantly, these molecules are readily accessible for academic researchers, with the possibility to request up to 40 samples on a monthly basis.</p><p id="P6">We employed the Glide [<xref ref-type="bibr" rid="R25">25</xref>] SP docking program to target the MTase binding site, as depicted in <xref rid="F1" ref-type="fig">Figure I</xref>. This approach allowed us to evaluate all the molecules in the ligand library. To enhance the reliability of our findings, we rigorously examined the top 1,000 molecules—those displaying the lowest docking scores—using the Glide XP setting to increase precision. Subsequently, we selected the top 100 performing molecules for further consideration, factoring in aspects such as diversity (see Methods: Docking V A, compound availability, and docking scores. In an effort to further refine our selection and improve the accuracy of binding prediction, we conducted a Molecular Mechanics Generalized Born Surface Area (MM/GBSA) analysis [<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R15">15</xref>] (see Methods: MM/GBSA Calculation V B). This step assisted us in narrowing down our list to the top 40 compounds, which we subsequently obtained from the NCI. <xref ref-type="supplementary-material" rid="SD1">Supplementary Table S2</xref> lists the selected compounds, along with their corresponding docking scores and Molecular Mechanics Generalized Born Surface Area (MM/GBSA) binding affinities. Notably, NSC620333 stood out, showcasing the most promising results, as demonstrated by its lowest docking and MM/GBSA scores. In <xref rid="F2" ref-type="fig">Figure 2</xref>, we provide the docked poses and 2D interaction diagrams of the three well performing inhibitors. These 2D interaction diagrams highlight the fact that the majority of residues in the binding pocket are hydrophobic or non-polar. Detailed information regarding the docking procedure and protein preparation can be found in the Methods section (see Methods: Docking V A).</p></sec><sec id="S4"><label>B</label><title>Experimental Evaluation of Lead Compounds</title><p id="P7">In this study, we harnessed both the precision and accuracy of a state-of-the-art high-throughput radioactivity-based assay [<xref ref-type="bibr" rid="R21">21</xref>], to experimentally test the MTase activity of nsp14 under the influence of our selected compounds. Out of the 40 assessed compounds, seven manifested inhibitory properties (<xref rid="T1" ref-type="table">Table I</xref>). Among these, NSC76988 and NSC620333 emerged as particularly promising candidates, due to their relatively low IC<sub>50</sub> values 6 and 5 <italic>μ</italic>M, respectively, suggestive of a potent inhibitory effect. To further substantiate these findings and confirm the binding of these inhibitors to nsp14, we employed surface plasmon resonance (SPR). [<xref ref-type="bibr" rid="R26">26</xref>]. This technique was leveraged to investigate the binding interactions of the top four compounds from the radioactivity-based assay. <xref rid="F2" ref-type="fig">Figure 2</xref> provides detailed insight into these molecular interactions. It presents the 2D structural diagrams of the top four experimentally validated compounds that inhibit MTase activity. Alongside these are the 2D interaction diagrams derived from docking studies, and 3D poses showing how these compounds fit within the lateral cavity of nsp14. Interestingly, of these four inhibitors, NSC620333 had the lowest <italic>K</italic><sub><italic>D</italic></sub> value of 544 ± 22 nM (cf. <xref rid="F3" ref-type="fig">Figures 3</xref> and <xref ref-type="supplementary-material" rid="SD1">S1</xref>). This observation points to the potential of NSC620333 as an effective nsp14 inhibitor. Moreover, the results from batch re-testing with a purified sample of NSC620333 provide compelling reinforcement of this proposition, as depicted in <xref ref-type="supplementary-material" rid="SD1">Supplementary Figures S3</xref> and <xref ref-type="supplementary-material" rid="SD1">S6</xref>.</p><p id="P8">In the quest to further understand the specificity of NSC620333, we evaluated its inhibitory activity against a diverse panel of 33 human RNA-, DNA-, and protein-MTases (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table S3</xref>). A critical part of our investigation focused on potential off-target effects within the host to ensure the safety and efficacy of the compounds. Our analyses revealed that NSC620333 selectively inhibited only human RNMT [<xref ref-type="bibr" rid="R27">27</xref>] (N<sup>7</sup> guanosine RNA methyltransferase) and PRMT7 [<xref ref-type="bibr" rid="R28">28</xref>] (protein arginine methyltransferase 7), with IC<sub>50</sub> values of 8.6 <italic>±</italic> 1.3 and 7 <italic>±</italic> 1.5 <italic>μ</italic>M, respectively (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>). Notably, RNMT is involved in the process of mRNA capping, which is essential for maintaining mRNA stability, facilitating its export, and ensuring efficient translation [<xref ref-type="bibr" rid="R29">29</xref>]. In contrast, PRMT7 participates in the methylation of arginine residues on specific proteins, thereby impacting cellular processes such as gene transcription, DNA repair, and signal transduction [<xref ref-type="bibr" rid="R30">30</xref>]. Furthermore, to extrapolate our <italic>in vitro</italic> findings to a physiologically-relevant context, we tested NSC620333 and NSC76988 in an in <italic>vivo assay</italic>. This experiment was based on a lung epithelial SARS-CoV-2 infection model using Calu-3 cells. Encouragingly, both compounds demonstrated anti-SARS-CoV-2 activity (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S5</xref>), providing supportive evidence for their potential as therapeutic agents. Taken together, the data from all three complementary assays converges towards a common conclusion: NSC620333 stands out as a potential therapeutic candidate against SARS-CoV-2. This compound exhibited a potent inhibitory effect, significant binding to nsp14, favorable selectivity, and in vivo efficacy. These promising attributes warrant further investigations into its potential for clinical application in SARS-CoV-2 treatment. On a separate note, it is interesting to observe that while no direct binding was detected between NSC76988 and nsp14, the compound displayed no-table inhibitory effects. However, the mechanism of such inhibition is unclear.</p></sec><sec id="S5"><label>C</label><title>MD Simulations of nsp14</title><p id="P9">Structural insights into nsp14 were obtained through molecular dynamics (MD) simulations performed under three different conditions: (i) the protein only, (ii) the protein in complex with NSC620333, and (iii) nsp14 in/out of complex with metal coordination complexes. Our findings are presented as follows:</p><sec id="S6"><label>1</label><title>Protein dynamics</title><p id="P10">Investigations into ligand binding within the MTase lateral cavity were conducted via numerous extended molecular dynamics simulations of the nsp14-nsp10 complex, all performed under a consistent thermal condition of 303.15 <italic>K</italic> (details in Methods: Molecular Dynamics Simulations V G). Throughout these simulations, we monitored the average motion of residues located within a 5-angstrom radius of the SS148 binding region, as depicted in <xref rid="F4" ref-type="fig">Figure 4</xref>(A). A thorough evaluation of the complete motion of the associated residues is presented in <xref ref-type="supplementary-material" rid="SD1">Supplementary Figures S7</xref>. Interestingly, we found that residues Phe367, Tyr368, and Gln354 on average exhibited the most significant movement across all simulations. These residues displayed considerable stabilization when NSC620333 was present in the binding pocket. Specifically, the root-mean-square deviation (RMSD) movement of Phe367, Tyr368, and Gln354 reduced to 0.25, 0.29, and 0.26 angstroms respectively in the presence of NSC620333. Significantly, we observed a limited number of conformational changes in the nsp10 protein when it was complexed with nsp14 (see <xref rid="F4" ref-type="fig">Figure 4</xref>(B) (Left)), indicating a high level of interaction stability between the two proteins based on our sampling. <xref rid="F4" ref-type="fig">Figure 4</xref>(B) (Middle/Right) showcases the key residues involved in this interaction. Specifically, Phe24, Glu11, His85, Thr10, and Val26 were identified as the most crucial residues facilitating this interaction.</p></sec><sec id="S7"><label>2</label><title>Conformational Shifts</title><p id="P11">To gain a more comprehensive understanding of the conformational dynamics of the nsp14 complex, we conducted an in-depth analysis of the gathered molecular dynamics simulations [<xref ref-type="bibr" rid="R16">16</xref>]. This process involved amalgamating data from receptor-ligand simulations to scrutinize the specific dynamics of the MTase binding cavity and, in a separate analysis, the overall dynamics of the complex backbone across independent trajectories [<xref ref-type="bibr" rid="R31">31</xref>]. We employed time-lagged independent component analysis (tICA) to project pertinent trajectory features onto a lower-dimensionality landscape, which facilitated clustering and visualization of the sampled metastable states [<xref ref-type="bibr" rid="R32">32</xref>]. The features of the binding pocket were defined by pairwise distances between the heavy atoms of the NSC620333 ligand and the backbone <italic>α</italic>-carbons of 27 crucial residues within the MTase lateral cavity. The analysis of global dynamics similarly employed pairwise distances between <italic>α</italic>-carbons. The generated projections were clustered using the K-means algorithm [<xref ref-type="bibr" rid="R33">33</xref>], resulting in eight states that spanned the sampled landscape and were aligned for comparative visualization. In both instances, the cluster with the highest population (comprising approximately 60% of the frames) closely mirrored the anticipated native state, with one or two additional states constituting the majority of the remaining configurations. The visualization of the states underpinning global dynamics revealed that nsp10 and the exoribonuclease domain of nsp14 remained stable. In contrast, the MTase domain exhibited a bent configuration in a minor proportion of frames. The comparative analysis between trajectories both devoid of metal ions and those inclusive of metal ions yielded consistent overall dynamics (see Methods: Molecular Dynamics Simulations V G). However, a larger bend of the main alpha-helix MTase was observable in a more significant population for ion-inclusive trajectories, as evidenced by Cluster 5 and Cluster 7 in <xref rid="F5" ref-type="fig">Figure 5</xref> (4.6% vs. approximately 1%). This analysis showcases the influence of metal ion presence on the conformational flexibility of the MTase domain, shedding light on the critical role of coordination complex ions in regulating protein structure and dynamics.</p></sec><sec id="S8"><label>3</label><title>Structural Insights into Inhibition</title><p id="P12">The application of tICA decomposition on protein-ligand interactions in the simulations identified a variety of binding poses for NSC620333 within the nsp14 MTase binding cavity. From this analysis, eight distinct clusters emerged, which were further refined into three primary states, each visualized in <xref rid="F6" ref-type="fig">Figure 6</xref>. Detailed examination of these states facilitated the identification of specific interactions that contribute to the increased binding affinity of NSC620333, as supported by Wagner et al. [<xref ref-type="bibr" rid="R34">34</xref>]. Of particular interest were the hydrogen bonds observed to form from ASN538 to the purine group of the ligand, and the favorable lipophilic interactions of the chlorobenzene component of the ligand with the lipophilic subpocket, predominantly in Cluster 2 and Cluster 6 [<xref ref-type="bibr" rid="R35">35</xref>]. These interactions seem to play a crucial role in establishing a more stable binding configuration. Moreover, the varied poses of NSC620333 within the binding pocket further underscore the flexibility of the nsp14 MTase binding cavity, a factor that could be key in the design of effective therapeutic agents [<xref ref-type="bibr" rid="R36">36</xref>]. The presence of different binding modes, each with unique interaction profiles, may influence the ligand’s functional impact on the protein, potentially offering multiple pathways for pharmacological intervention [<xref ref-type="bibr" rid="R37">37</xref>].</p></sec></sec></sec><sec id="S9"><label>III</label><title>Crystal Structure of NSP14 Mtase in Complex with SS148</title><p id="P13">To uncover the atomic details of the nsp14-SS148 interaction, we performed the crystallographic analysis of the nsp14/SS148 complex. We employed the fusion protein-assisted crystallization approach using the MTase domain of nsp14 (residues 300-527) N-terminally fused to a small crystallization tag TELSAM developed by Kottur et al. [<xref ref-type="bibr" rid="R38">38</xref>]. The nsp14 MTase-TELSAM/SS148 crystals belonged to the hexagonal P65 space group and diffracted to the 2.6 Å resolution. The structure of the nsp14 MTase-TELSAM/SS148 complex was subsequently solved by molecular replacement and further refined to good R factors and geometry, as summarized in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table S4</xref>.</p><p id="P14">The SS148 ligand was bound to the SAM/SAH-binding site of nsp14 as expected (<xref rid="F7" ref-type="fig">Fig 7a</xref>). The structure of SS148 is derived from SAH and thus, the mechanism of its interaction with nsp14 is also similar to SAH. The nsp14-SS148 interaction is mediated by multiple interactions including both direct (via Asp352, Ala353, Tyr368, and Trp385) and indirect water-mediated hydrogen bonds (via Gln313, Asp331, and Ile332) (<xref rid="F7" ref-type="fig">Fig 7b</xref>). The amino acid moiety of SS148 binds to nsp14 amino acid residues Gln313, Trp385, and Asp331, while the central ribose-derived moiety of nsp14 interacts mainly with Asp352, and the basic adenine-derived moiety binds to Ala353 and Tyr368.</p><p id="P15">Compared to SAH, SS148 contains a nitrile group bound to the C7-position of the 7-deaza-adenine heterocyclic moiety. This nitrile group is bound to nsp14 in the groove formed by the nsp14 residues Phe367, Asn388, and Val389 (<xref rid="F7" ref-type="fig">Fig 7c</xref>). Our study documents that introduction of substituents at the C7-position of this 7-deaza-adenine moiety, physically larger than the presented nitrile group, can be a promising strategy potentially leading to development of more potent and more specific nsp14 inhibitors.</p><p id="P16">SS148 is an inhibitor with dual activity against both SARS-CoV-2 N7-MTase nsp14 and 2’-O-MTase nsp16. Therefore, we compared the SS148 binding site of nsp14 with the previously crystallized SS148 binding site of nsp16 [<xref ref-type="bibr" rid="R22">22</xref>] (<xref rid="F7" ref-type="fig">Fig 7d</xref>). Despite significant differences in the organization of the SS148 binding pockets in nsp14 and nsp16, we observed similar conformation of SS148. The conserved catalytic tetrad characteristic for 2’-O-MTases formed by Lys46, Asp130, Lys170, and Glu203 in nsp16 is not present in nsp14.</p><p id="P17">To judge the reliability of our computational pipeline, we performed re-docking of SS148 onto the nsp14 binding site. Our methodological approach was successful in accurately replicating the binding pose of the SS148 ligand within the nsp14 binding site, showcasing a striking alignment (RMSD 1.426Å) with the experimentally determined crystal structure (depicted in <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S4</xref>). The high degree of concordance between the computationally determined re-docking pose and the experimental crystal structure attests to the robustness of our docking pipeline methodology. The agreement between our computational predictions and experimental findings underscores the proficiency of our integrated approach and further substantiates the potential of SS148 as a promising dual inhibitor of SARS-CoV-2 MTases.</p></sec><sec id="S10"><label>IV</label><title>Conclusion and Outlook</title><p id="P18">Our comprehensive study has provided valuable insights into the complex dynamics of the SARS-CoV-2 nsp14 protein and the therapeutic potential of compounds aimed at inhibiting it. In particular, we found that the compound NSC620333 demonstrates promising attributes as a therapeutic agent against SARS-CoV-2, primarily due to its potent inhibitory effects on the nsp14 Methyltransferase (MTase) activity and its substantial binding affinity to nsp14. The observed in-vivo efficacy and selectivity of this compound for development of therapeutics in treating COVID-19. In our study, we identified several critical residues within the MTase binding pocket of nsp14, and elucidated their dynamic behavior in the presence of potential inhibitors, such as NSC620333. Our findings lay a solid foundation for future drug design efforts, paving the way for the development of novel strategies to disrupt the nsp14 function. This could potentially lead to new therapeutic options for COVID-19.</p><p id="P19">Interestingly, we observed conformational changes in nsp14, particularly in the presence and absence of metal coordination complexes, which emphasizes the role of this metal ion in the structural dynamics of nsp14. The diverse binding poses of the NSC620333 ligand identified in our study highlight the necessity for a dynamic view of protein-ligand interactions. It suggests that a single static view of a protein-ligand complex is insufficient to capture the full complexity of these interactions, further emphasizing the value of molecular dynamics simulations in comprehending these systems. Our structural studies also revealed the binding mechanism of another potential inhibitor, SS148. By visualizing its binding mode and interactions with nsp14, we proposed that introducing substituents at the C7-position of the 7-deaza-adenine moiety could enhance the potency and specificity of nsp14 inhibitors. The crystal structure also revealed the differences and similarities in the SS148 binding site between nsp14 and nsp16, providing valuable structural insights for drug design.</p><p id="P20">While our results are promising, they represent only the initial steps in a much longer journey. Further studies are needed to fully understand the therapeutic potential of these compounds. Future work should focus on optimizing these lead compounds, assessing their pharmacokinetic and pharmacodynamic properties, and evaluating their safety and efficacy in pre-clinical and clinical trials. Furthermore, the mechanistic exploration of NSC76988 and its potential allosteric mode of inhibition should also be pursued. Overall, this study underscores the potential of computational methods in understanding the complexities of biological systems and guiding the development of new therapeutics. We hope that our findings will inspire and inform future research efforts towards the development of effective treatments for COVID-19 and potentially other related viral threats.</p></sec><sec id="S11" sec-type="methods"><label>V</label><title>Methods</title><sec id="S12"><label>A</label><title>Docking</title><p id="P21">The Cryo-EM structure of SARS-CoV-2 nsp10-nsp14 (PDB:7N0B [<xref ref-type="bibr" rid="R39">39</xref>]) was utilized as a reference for molecular docking. The receptor was prepared through Schrödinger’s protein preparation tool [<xref ref-type="bibr" rid="R40">40</xref>], which involved a series of critical steps. These steps included modeling missing residues, capping missing termini, removing water molecules, and assigning protonation states. The ligand binding site was identified by superimposing SAM/SAH (PDB: 5C8S/5C8T [<xref ref-type="bibr" rid="R41">41</xref>]) onto the Cryo-EM structure. Upon completion of the overlay, a minimization was performed using the OPLS4 force field [<xref ref-type="bibr" rid="R42">42</xref>].</p><p id="P22">The process aimed to optimize the overall structure of the receptor-ligand complex, minimize potential clashes, and maximize binding interactions. For the molecular docking process, we employed Glide-SP and Glide-XP software [<xref ref-type="bibr" rid="R25">25</xref>], integrated within the VirtualFlow Unity [<xref ref-type="bibr" rid="R20">20</xref>] (VFU) pipeline (<ext-link ext-link-type="uri" xlink:href="https://github.com/VirtualFlow/VFU">https://github.com/VirtualFlow/VFU</ext-link>). In the interest of scientific inclusivity, we provide a VFU setup that utilizes QuickVina [<xref ref-type="bibr" rid="R43">43</xref>] and Smina [<xref ref-type="bibr" rid="R44">44</xref>], two open-source docking programs.</p><p id="P23">The NCI Open Compound collection was procured from NCBI PubChem (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>) by selecting “DTP/NCI” as the Data Source. The provided isomeric smiles were employed as starting points for processing the initial 250,000 molecules. At the stage of identifying the top-100 molecules, the molecules were manually inspected to ensure correct stereochemistry.</p><p id="P24">Diversity for a set of molecules was calculated as: <disp-formula id="FD1"><label>(1)</label><mml:math id="M1"><mml:mrow><mml:mtext>Diversity</mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mn>2</mml:mn><mml:mrow><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:munder><mml:mi>∑</mml:mi><mml:mrow><mml:mi>X</mml:mi><mml:mo>,</mml:mo><mml:mi>Y</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mtext>sim</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>X</mml:mi><mml:mo>,</mml:mo><mml:mi>Y</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p id="P25">The expression sim(<italic>X, Y</italic>) computes the pairwise molecular similarity for all <italic>n</italic> structures calculated as the Tanimoto distance of the Morgan fingerprint (calculated with a radius of size 3 and a 2048 bit size) [<xref ref-type="bibr" rid="R45">45</xref>].</p></sec><sec id="S13"><label>B</label><title>MM/GBSA Calculation</title><p id="P26">The AMBER ff14SB force field [<xref ref-type="bibr" rid="R46">46</xref>] and the General AM-BER force field (GAFF2) [<xref ref-type="bibr" rid="R47">47</xref>] were employed for parameterizing proteins and ligands, respectively, in the complex systems. The antechamber module [<xref ref-type="bibr" rid="R48">48</xref>] was utilized to calculate the partial atomic charges using the AM1-BCC charge model for ligand molecules. To eliminate bad steric contacts, the systems were subjected to energy minimization with the steepest descent algorithm and conjugate gradient methods, without restraints. This process involved 2,500 iterations using the Sander MD engine [<xref ref-type="bibr" rid="R49">49</xref>]. The MM/GBSA energies were evaluated using the MMPBSA.py [<xref ref-type="bibr" rid="R14">14</xref>] script, which is part of the AmberTools21 package [<xref ref-type="bibr" rid="R50">50</xref>].</p></sec><sec id="S14"><label>C</label><title>Protein Expression and Purification</title><p id="P27">The SARS-CoV-2 nsp14 MTase domain-encoding sequence (GenBank: YP 009725309.1, residues 300-527) was codon-optimized for expression in <italic>E. coli</italic> and synthesized by GeneArt (Thermo Scientific). The gene was cloned into a modified pRSFDuet vector containing an N-terminal hexahistidine (His6) purification tag, followed by a SUMO solubility and folding tag, and a TELSAM crystallization tag [<xref ref-type="bibr" rid="R38">38</xref>]. The plasmid was transformed into <italic>E. coli</italic> BL21 DE3 NiCo bacterial strain (New England Biolabs), and the protein was overexpressed using autoinduction ZY medium. Cells were collected by centrifugation and resuspended in lysis buffer (50 mM Tris, pH 8.0, 400 mM NaCl, 20 mM imidazole, 10 mM MgCl<sub>2</sub>, 10 <italic>μ</italic>M ZnCl<sub>2</sub>, 3 mM <italic>β</italic>-mercaptoethanol, and 250U of DNA endonuclease DENERASE (c-LEcta)). The cells were then sonicated using the Q700 Sonicator instrument (QSonica). The lysate was subsequently cleared by centrifugation, and the supernatant was incubated with Ni-NTA agarose (Thermo Scientific), followed by extensive washing with lysis buffer. The protein was finally eluted using lysis buffer supplemented with 300 mM imidazole. Post-elution, the protein was treated with Ulp1 protease to cleave off the His6-SUMO tag. The nsp14 MTase-TELSAM protein was further purified by size exclusion chromatography using Superdex 200 16/600 (GE Healthcare) pre-equilibrated with size-exclusion buffer (25 mM Tris pH 8.3, 200 mM KCl, and 2 mM TCEP). Fractions containing the nsp14 MTase-TELSAM protein were concentrated to 4 mg/ml, flash-frozen, and stored at −80°C.</p></sec><sec id="S15"><label>D</label><title>Crystallization and Crystallographic Analysis</title><p id="P28">Crystallization trials were conducted with a concentration of 4 mg/ml of the nsp14 MTase-TELSAM protein, supplemented with a twofold molar excess of the SS148 ligand. Crystals were observed to grow within two days at 18°C. This was achieved in a sitting drop composed of a 200 nl mixture of the protein and 200 nl of the mother liquor, which contained 100 mM bicine/Trizma pH 8.5; 10% w/v PEG 20,000; 20% v/v PEG MME 550; 20 mM D-glucose; 20 mM D-mannose; 20 mM D-galactose; 20 mM L-fucose; 20 mM D-xylose; 20 mM N-acetyl-D-glucosamine.</p><p id="P29">The crystallographic dataset was collected from a single crystal at the BL14.1 beamline, located at the BESSY II electron storage ring operated by Helmholtz-Zentrum Berlin [<xref ref-type="bibr" rid="R51">51</xref>]. Data integration and scaling were performed using XDS [<xref ref-type="bibr" rid="R52">52</xref>]. Molecular replacement was used to solve the structure of the nsp14 MTase-TELSAM/SS148 complex, with the nsp14 MTase-TELSAM/sinefungin complex structure serving as the search model (PDB entry 7TW9 [<xref ref-type="bibr" rid="R38">38</xref>]). Phaser from the Phenix package was used for the initial model [<xref ref-type="bibr" rid="R53">53</xref>, <xref ref-type="bibr" rid="R54">54</xref>]. Model improvement was accomplished via automatic model refinement with Phenix.refine [<xref ref-type="bibr" rid="R55">55</xref>] and manual model building with Coot [<xref ref-type="bibr" rid="R56">56</xref>]. Statistics regarding data collection, structure solution, and refinement are provided in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table S4</xref>. Structural figures were generated using PyMOL Molecular Graphics System v2.5 (Schrödinger, LLC) [<xref ref-type="bibr" rid="R57">57</xref>]. The atomic coordinates and structural factors have been deposited in the Protein Data Bank (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org">https://www.rcsb.org</ext-link>) under the accession code 8BWU.</p></sec><sec id="S16"><label>E</label><title>Radioactivity-based Assay Conditions</title><p id="P30">The assay conditions for nsp14 were as follows: The final concentrations in the reaction mixture were 1.5 nM for nsp14, 50 nM for Biotin-RNA (<italic>5’GpppACCCCCCCCC-Biotin 3’</italic>), and 250 nM for <sup>3</sup>H-SAM. The incubation was carried out for 20 minutes at 23°C. The buffer used con-tained 20 mM Tris HCl at pH 7.5, 250 <italic>μ</italic>M MgCl<sub>2</sub>, 5 mM DTT, and 0.01% Triton X-100, with an additional 5% DMSO.</p></sec><sec id="S17"><label>F</label><title>SPR Conditions</title><p id="P31">For Surface Plasmon Resonance (SPR), the full-length biotinylated nsp14 was immobilized on the flow cell of a SA sensor chip in 1x HBS-EP buffer, achieving a response of 8000 RU. The assay was performed using the same buffer but with 2% DMSO added. Single-cycle kinetics were employed with a contact time of 60 seconds and a dissociation time of 120 seconds, at a flow rate of 75 <italic>μ</italic>L/min. NSC620333 was tested at a concentration of 10 <italic>μ</italic>M as the highest concentration, and a dilution factor of 0.25 was used to yield five different concentrations.</p></sec><sec id="S18"><label>G</label><title>Molecular Dynamics Simulations</title><p id="P32">The crystal structure of nsp14 in complex with nsp10 was obtained from the Protein Data Bank (PDB) under the entry code 7N0B. All missing residues and variants relative to the wild-type were modeled using Schrodinger’s protein preparation tool. The RNA complex was removed for the purposes of our simulations. The system was solvated in a periodic cubic box containing TIP3P water with 150 mM KCl using CHARMM-GUI [<xref ref-type="bibr" rid="R58">58</xref>]. The CHARMM36m force field [<xref ref-type="bibr" rid="R59">59</xref>] with hydrogen mass repartitioning was employed, and input files were sourced directly from CHARMM-GUI. Molecular dynamics simulations were performed using the Gromacs 2020.3 software package [<xref ref-type="bibr" rid="R60">60</xref>]. The simulations employed a Langevin thermostat and a Nosé–Hoover Langevin piston barostat to maintain a pressure of 1 atm. Long-range interactions were treated using the particle mesh Ewald method, and non-bonded interactions were smoothed between 10 to 12 Å. The system underwent energy minimization for 1,500 steps, followed by equilibration to 303.15K with a timestep of 2 fs for 10 ns using the SHAKE and SET-TLE algorithms [<xref ref-type="bibr" rid="R61">61</xref>]. Production simulations were conducted with a 4 fs timestep for a total of 1.0 <italic>μ</italic>s, with five independent replicates. Simulations that included NSC620333 were parameterized using the Charmm General Force Field (CGenFF) framework [<xref ref-type="bibr" rid="R62">62</xref>]. Throughout the simulations, the root-mean-square deviation (RMSD) of the protein residues was calculated using the MDTraj package [<xref ref-type="bibr" rid="R63">63</xref>]. All our simulations can be downloaded from: <ext-link ext-link-type="uri" xlink:href="https://drive.google.com/drive/folders/1tKiIsDxBbjZLCxceSoDXlJAczd4UgHIJ?usp=sharing">https://drive.google.com/drive/folders/1tKiIsDxBbjZLCxceSoDXlJAczd4UgHIJ?usp=sharing</ext-link>.</p></sec><sec id="S19"><label>H</label><title>Anti-SARS-CoV-2 and Cytotoxicity Assays in Calu-3 Cells</title><p id="P33">Anti-SARS-CoV-2 activity of NSC620333 and NSC76988 compounds were determined in the human lung adenocarcinoma cell line Calu-3 (ATCC, cat. no. HTB-55) using SARS-CoV-2 (isolate hCoV-19/Czech Republic/NRL 6632 2/2020). Briefly, two-fold eight serial dilutions of the compounds starting from 100 <italic>μM</italic> were added to 40, 000 Calu-3 cells seeded for 1 day in DMEM supplemented with 2% fetal bovine serum, 100 <italic>U</italic> of penicillin/mL and 100 <italic>μg</italic> of streptomycin/mL. After 1 <italic>h</italic> incubation at 37 °C, SARS-CoV-2 was added at a multiplicity of infection (MOI) of 0.03 IU/ml, incubated 3 days at 37 °C, and the virus-induced cytopathic effect (CPE) was quantified by formazan-based cell viability assay (XTT assay). XTT solution was added and after 4 <italic>h</italic> incubation, the absorbance at 450 nm was measured using the EnVision plate reader. After plotting the percentage cell viability versus log<sub>10</sub> concentrations, the compound concentrations required to reduce viral cytopathic effect by 50% (EC50) were calculated by nonlinear regression. To determine compound cytotoxicity, Calu-3 cells were exposed to the same compound dilutions as above but without virus, and cell viability was determined using XTT assay. The compound concentrations causing 50% reduction in cell viability (CC50) were calculated similarly. Three-fold serial dilutions of Remdesivir from 10 <italic>μM</italic> served as a control in both experiments.</p></sec><sec id="S20"><label>I</label><title>Assay Technique</title><p id="P34">The MTase activity of nsp14 was measured using a radiometric assay as described previously [<xref ref-type="bibr" rid="R21">21</xref>]. Chlorobenzothiophene 3 was tested at various concentrations ranging from 200 nM to 200 <italic>μ</italic>M to determine the half-maximal inhibitory concentration (IC<sub>50</sub>) value. The final reaction mixture consisted of 1.5 nM nsp14, 250 nM <sup>3</sup>H-SAM, and 50 nM RNA in buffer (20 mM Tris HCl, pH 7.5, 250 <italic>μ</italic>M MgCl<sub>2</sub>, 5 mM DTT, and 0.01% Triton X-100). The reaction time was 20 min at 23°C. Data were fitted to the four-parameter logistic equation using GraphPad Prism 8.</p></sec><sec id="S21"><label>J</label><title>Synthesis of SS148</title><p id="P35">The synthesis of SS148 (also referred to as CN-SAH in the literature) was carried out according to previously published procedures [<xref ref-type="bibr" rid="R64">64</xref>]. Comprehensive synthetic procedures and associated 1H and 13C -NMR data for SS148 can be found in the referenced literature.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Information</label><media xlink:href="EMS189149-supplement-Supplementary_Information.pdf" mimetype="application" mime-subtype="pdf" id="d23aAdFbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S22"><title>Acknowledgements</title><p>AK.N. acknowledges funding from the Bio-X Stanford Interdisciplinary Graduate Fellowship (SGIF). Special thanks are extended to A.K. and Michael Bassik for their invaluable assistance in securing the SGIF funding. R.P. acknowledges funding through a Postdoc.Mobility fellowship by the Swiss National Science Foundation (SNSF, Project No. 191127). A.A.-G. thanks Dr. Anders G. Frøseth for his generous support. A.A.-G. also acknowledges the generous support of Natural Resources Canada and the Canada 150 Research Chairs program. M.F.D.H and V.A.V were supported in part by the National Institutes of Health grant 1R01GM123296. One part of the parameterization of simulations was performed on HPC resources supported in part by the National Science Foundation through major research instrumentation grant number 1625061 and by the US Army Research Laboratory under contract number W911NF-16-2-0189. The remaining parameterization was performed on the CB2RR cluster made possible through NIH Research Resource computer instrumentation grant S10-OD020095. S.S. is a Damon Runyon Quantitative Biology Fellow supported by the Damon Runyon Cancer Research Foundation (DRQ-14-22). This research was enabled in part by support provided by Calcul Québec (<ext-link ext-link-type="uri" xlink:href="https://www.calculquebec.ca">https://www.calculquebec.ca</ext-link>) and Compute Canada (<ext-link ext-link-type="uri" xlink:href="http://www.computecanada.ca">www.computecanada.ca</ext-link>). HN acknowledges NVIDIA and Intel for funding. MD simulations for all compounds were performed on the Béluga supercomputer situated at the École de technologie supérieure in Montreal. We thank the Helmholtz-Zentrum Berlin für Materialien und Energie for the allocation of synchrotron radiation beamtime. This work was supported by the project National Institute Virology and Bacteriology (Programme EXCELES, Project No. LX22NPO5103) - Funded by the European Union - Next Generation EU. The research was also, in part, made possible thanks to funding provided to the University of Toronto’s Acceleration Consortium by the Canada First Research Excellence Fund (CFREF-2022-00042).</p></ack><ref-list><ref id="R1"><label>[1]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paules</surname><given-names>Catharine I</given-names></name><name><surname>Marston</surname><given-names>Hilary D</given-names></name><name><surname>Fauci</surname><given-names>Anthony S</given-names></name></person-group><article-title>Coronavirus infections—more than just the common cold</article-title><source>Jama</source><year>2020</year><volume>323</volume><issue>8</issue><fpage>707</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">31971553</pub-id></element-citation></ref><ref id="R2"><label>[2]</label><element-citation publication-type="journal"><collab>World Health Organization</collab><etal/><article-title>The corona virus disease 2019 (covid-19)</article-title><source>Brazilian Journal of Implantology and Health Sciences</source><year>2022</year><volume>4</volume><issue>6</issue><fpage>45</fpage><lpage>46</lpage></element-citation></ref><ref id="R3"><label>[3]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>Atul</given-names></name><name><surname>Tiwari</surname><given-names>Swapnil</given-names></name><name><surname>Deb</surname><given-names>Manas Kanti</given-names></name><name><surname>Marty</surname><given-names>Jean Louis</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus-2 (sars-cov-2): a global pandemic and treatment strategies</article-title><source>International journal of antimicrobial agents</source><year>2020</year><volume>56</volume><issue>2</issue><elocation-id>106054</elocation-id><pub-id pub-id-type="pmcid">PMC7286265</pub-id><pub-id pub-id-type="pmid">32534188</pub-id><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106054</pub-id></element-citation></ref><ref id="R4"><label>[4]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naqvi</surname><given-names>Ahmad Abu Turab</given-names></name><name><surname>Fatima</surname><given-names>Kisa</given-names></name><name><surname>Mohammad</surname><given-names>Taj</given-names></name><name><surname>Fatima</surname><given-names>Urooj</given-names></name><name><surname>Singh</surname><given-names>Indrakant K</given-names></name><name><surname>Singh</surname><given-names>Archana</given-names></name><name><surname>Atif</surname><given-names>Shaikh Muhammad</given-names></name><name><surname>Hariprasad</surname><given-names>Gururao</given-names></name><name><surname>Hasan</surname><given-names>Gulam Mustafa</given-names></name><name><surname>Hassan</surname><given-names>Md Imtaiyaz</given-names></name></person-group><article-title>Insights into sars-cov-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach</article-title><source>Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease</source><year>2020</year><volume>1866</volume><issue>10</issue><elocation-id>165878</elocation-id><pub-id pub-id-type="pmcid">PMC7293463</pub-id><pub-id pub-id-type="pmid">32544429</pub-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2020.165878</pub-id></element-citation></ref><ref id="R5"><label>[5]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>Teresa I</given-names></name><name><surname>Correia</surname><given-names>Ivan</given-names></name><name><surname>Seagal</surname><given-names>Jane</given-names></name><name><surname>De-Goey</surname><given-names>David A</given-names></name><name><surname>Schrimpf</surname><given-names>Michael R</given-names></name><name><surname>Hardee</surname><given-names>David J</given-names></name><name><surname>Noey</surname><given-names>Elizabeth L</given-names></name><name><surname>Kati</surname><given-names>Warren M</given-names></name></person-group><article-title>Antiviral drug discovery for the treatment of covid-19 infections</article-title><source>Viruses</source><year>2022</year><volume>14</volume><issue>5</issue><fpage>961</fpage><pub-id pub-id-type="pmcid">PMC9143071</pub-id><pub-id pub-id-type="pmid">35632703</pub-id><pub-id pub-id-type="doi">10.3390/v14050961</pub-id></element-citation></ref><ref id="R6"><label>[6]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouvet</surname><given-names>Mickaël</given-names></name><name><surname>Debarnot</surname><given-names>Claire</given-names></name><name><surname>Imbert</surname><given-names>Isabelle</given-names></name><name><surname>Selisko</surname><given-names>Bar-bara</given-names></name><name><surname>Snijder</surname><given-names>Eric J</given-names></name><name><surname>Canard</surname><given-names>Bruno</given-names></name><name><surname>Decroly</surname><given-names>Etienne</given-names></name></person-group><article-title>In vitro reconstitution of sars-coronavirus mrna cap methylation</article-title><source>PLoS pathogens</source><year>2010</year><volume>6</volume><issue>4</issue><elocation-id>e1000863</elocation-id><pub-id pub-id-type="pmcid">PMC2858705</pub-id><pub-id pub-id-type="pmid">20421945</pub-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000863</pub-id></element-citation></ref><ref id="R7"><label>[7]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Yu</given-names></name><name><surname>Cai</surname><given-names>Hui</given-names></name><name><surname>Pan</surname><given-names>Ji’an</given-names></name><name><surname>Xiang</surname><given-names>Nian</given-names></name><name><surname>Tien</surname><given-names>Po</given-names></name><name><surname>Ahola</surname><given-names>Tero</given-names></name><name><surname>Guo</surname><given-names>Deyin</given-names></name></person-group><article-title>Functional screen reveals sars coronavirus nonstructural protein nsp14 as a novel cap n7 methyltransferase</article-title><source>Proceedings of the National Academy of Sciences</source><year>2009</year><volume>106</volume><issue>9</issue><fpage>3484</fpage><lpage>3489</lpage><pub-id pub-id-type="pmcid">PMC2651275</pub-id><pub-id pub-id-type="pmid">19208801</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0808790106</pub-id></element-citation></ref><ref id="R8"><label>[8]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>Victor M</given-names></name><name><surname>Muth</surname><given-names>Doreen</given-names></name><name><surname>Niemeyer</surname><given-names>Daniela</given-names></name><name><surname>Drosten</surname><given-names>Christian</given-names></name></person-group><article-title>Hosts and sources of endemic human coronaviruses</article-title><source>Advances in virus research</source><year>2018</year><volume>100</volume><fpage>163</fpage><lpage>188</lpage><pub-id pub-id-type="pmcid">PMC7112090</pub-id><pub-id pub-id-type="pmid">29551135</pub-id><pub-id pub-id-type="doi">10.1016/bs.aivir.2018.01.001</pub-id></element-citation></ref><ref id="R9"><label>[9]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Delft</surname><given-names>Annette</given-names></name><name><surname>Hall</surname><given-names>Matthew D</given-names></name><name><surname>Kwong</surname><given-names>Ann D</given-names></name><name><surname>Purcell</surname><given-names>Lisa A</given-names></name><name><surname>Saikatendu</surname><given-names>Kumar Singh</given-names></name><name><surname>Schmitz</surname><given-names>Uli</given-names></name><name><surname>Tallarico</surname><given-names>John A</given-names></name><name><surname>Lee</surname><given-names>Alpha A</given-names></name></person-group><article-title>Accelerating antiviral drug discovery: lessons from covid-19</article-title><source>Nature Reviews Drug Discovery</source><year>2023</year><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="pmcid">PMC10176316</pub-id><pub-id pub-id-type="pmid">37173515</pub-id><pub-id pub-id-type="doi">10.1038/s41573-023-00692-8</pub-id></element-citation></ref><ref id="R10"><label>[10]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ihlenfeldt</surname><given-names>Wolf-Dietrich</given-names></name><name><surname>Voigt</surname><given-names>Johannes H</given-names></name><name><surname>Bienfait</surname><given-names>Bruno</given-names></name><name><surname>Oellien</surname><given-names>Frank</given-names></name><name><surname>Nicklaus</surname><given-names>Marc C</given-names></name></person-group><article-title>Enhanced cactvs browser of the open nci database</article-title><source>Journal of chemical information and computer sciences</source><year>2002</year><volume>42</volume><issue>1</issue><fpage>46</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">11855965</pub-id></element-citation></ref><ref id="R11"><label>[11]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voigt</surname><given-names>Johannes H</given-names></name><name><surname>Bienfait</surname><given-names>Bruno</given-names></name><name><surname>Wang</surname><given-names>Shaomeng</given-names></name><name><surname>Nicklaus</surname><given-names>Marc C</given-names></name></person-group><article-title>Comparison of the nci open database with seven large chemical structural databases</article-title><source>Journal of chemical information and computer sciences</source><year>2001</year><volume>41</volume><issue>3</issue><fpage>702</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">11410049</pub-id></element-citation></ref><ref id="R12"><label>[12]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagadala</surname><given-names>Nataraj S</given-names></name><name><surname>Syed</surname><given-names>Khajamohiddin</given-names></name><name><surname>Tuszynski</surname><given-names>Jack</given-names></name></person-group><article-title>Software for molecular docking: a review</article-title><source>Biophysical reviews</source><year>2017</year><volume>9</volume><fpage>91</fpage><lpage>102</lpage><pub-id pub-id-type="pmcid">PMC5425816</pub-id><pub-id pub-id-type="pmid">28510083</pub-id><pub-id pub-id-type="doi">10.1007/s12551-016-0247-1</pub-id></element-citation></ref><ref id="R13"><label>[13]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nigam</surname><given-names>AkshatKumar</given-names></name><name><surname>Pollice</surname><given-names>Robert</given-names></name><name><surname>Tom</surname><given-names>Gary</given-names></name><name><surname>Jorner</surname><given-names>Kjell</given-names></name><name><surname>Thiede</surname><given-names>Luca A</given-names></name><name><surname>Kundaje</surname><given-names>Anshul</given-names></name><name><surname>Aspuru-Guzik</surname><given-names>Alan</given-names></name></person-group><article-title>Tartarus: A benchmarking platform for realistic and practical inverse molecular design</article-title><source>arXiv preprint</source><year>2022</year><elocation-id>arXiv: 2209.12487</elocation-id></element-citation></ref><ref id="R14"><label>[14]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>Bill R</given-names><suffix>III</suffix></name><name><surname>McGee</surname><given-names>T Dwight</given-names><suffix>Jr</suffix></name><name><surname>Swails</surname><given-names>Jason M</given-names></name><name><surname>Homeyer</surname><given-names>Nadine</given-names></name><name><surname>Gohlke</surname><given-names>Holger</given-names></name><name><surname>Mmpbsa</surname><given-names>Adrian E Roitberg</given-names></name></person-group><article-title>py: an efficient program for end-state free energy calculations</article-title><source>Journal of chemical theory and com-putation</source><year>2012</year><volume>8</volume><issue>9</issue><fpage>3314</fpage><lpage>3321</lpage><pub-id pub-id-type="pmid">26605738</pub-id></element-citation></ref><ref id="R15"><label>[15]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ylilauri</surname><given-names>Mikko</given-names></name><name><surname>Pentik:”ainen</surname><given-names>Olli T</given-names></name></person-group><article-title>Mmgbsa as a tool to understand the binding affinities of filamin–peptide interactions</article-title><source>Journal of chemical information and modeling</source><year>2013</year><volume>53</volume><issue>10</issue><fpage>2626</fpage><lpage>2633</lpage><pub-id pub-id-type="pmid">23988151</pub-id></element-citation></ref><ref id="R16"><label>[16]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollingsworth</surname><given-names>Scott A</given-names></name><name><surname>Dror</surname><given-names>Ron O</given-names></name></person-group><article-title>Molecular dynamics simulation for all</article-title><source>Neuron</source><year>2018</year><volume>99</volume><issue>6</issue><fpage>1129</fpage><lpage>1143</lpage><pub-id pub-id-type="pmcid">PMC6209097</pub-id><pub-id pub-id-type="pmid">30236283</pub-id><pub-id pub-id-type="doi">10.1016/j.neuron.2018.08.011</pub-id></element-citation></ref><ref id="R17"><label>[17]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelpi</surname><given-names>J</given-names></name></person-group><collab>Hospital a, goñi r, orozco m</collab><article-title>Molecular dynamics simulations: Advances and applications</article-title><source>Advances and Applications in Bioinformatics and Chemistry</source><year>2015</year><volume>8</volume><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="pmcid">PMC4655909</pub-id><pub-id pub-id-type="pmid">26604800</pub-id><pub-id pub-id-type="doi">10.2147/AABC.S70333</pub-id></element-citation></ref><ref id="R18"><label>[18]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin-Konigsberg</surname><given-names>Roni</given-names></name><name><surname>Mitra</surname><given-names>Koushambi</given-names></name><name><surname>Nigam</surname><given-names>AkshatKumar</given-names></name><name><surname>Spees</surname><given-names>Kaitlyn</given-names></name><name><surname>Hivare</surname><given-names>Pravin</given-names></name><name><surname>Liu</surname><given-names>Katherine</given-names></name><name><surname>Kundaje</surname><given-names>Anshul</given-names></name><name><surname>Krishnan</surname><given-names>Yamuna</given-names></name><name><surname>Bassik</surname><given-names>Michael</given-names></name></person-group><article-title>Slc12a9 is a lysosome-detoxifying ammonium-chloride co-transporter</article-title><source>bioRxiv</source><year>2023</year><elocation-id>2023-05</elocation-id></element-citation></ref><ref id="R19"><label>[19]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogando</surname><given-names>Natacha S</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>Jessika C</given-names></name><name><surname>van der Meer</surname><given-names>Yvonne</given-names></name><name><surname>Bredenbeek</surname><given-names>Peter J</given-names></name><name><surname>Posthuma</surname><given-names>Clara C</given-names></name><name><surname>Snijder</surname><given-names>Eric J</given-names></name></person-group><article-title>The enzymatic activity of the nsp14 exoribonuclease is critical for replication of mers-cov and sars-cov-2</article-title><source>Journal of virology</source><year>2020</year><volume>94</volume><issue>23</issue><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="pmcid">PMC7654266</pub-id><pub-id pub-id-type="pmid">32938769</pub-id><pub-id pub-id-type="doi">10.1128/JVI.01246-20</pub-id></element-citation></ref><ref id="R20"><label>[20]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorgulla</surname><given-names>Christoph</given-names></name><name><surname>Nigam</surname><given-names>AkshatKumar</given-names></name><name><surname>Koop</surname><given-names>Matt</given-names></name><name><surname>Cinaroglu</surname><given-names>Suleyman S</given-names></name><name><surname>Secker</surname><given-names>Christopher</given-names></name><name><surname>Haddadnia</surname><given-names>Mohammad</given-names></name><name><surname>Kumar</surname><given-names>Abhishek</given-names></name><name><surname>Malets</surname><given-names>Yehor</given-names></name><name><surname>Hasson</surname><given-names>Alexander</given-names></name><name><surname>Levin-Konigsberg</surname><given-names>Roni</given-names></name><etal/></person-group><article-title>Virtualflow 2.0-the next generation drug discovery platform enabling adaptive screens of 69 billion molecules</article-title><source>bioRxiv</source><year>2023</year><elocation-id>2023-04</elocation-id></element-citation></ref><ref id="R21"><label>[21]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devkota</surname><given-names>Kanchan</given-names></name><name><surname>Schapira</surname><given-names>Matthieu</given-names></name><name><surname>Perveen</surname><given-names>Sumera</given-names></name><name><surname>Yazdi</surname><given-names>Aliakbar Khalili</given-names></name><name><surname>Li</surname><given-names>Fengling</given-names></name><name><surname>Chau</surname><given-names>Irene</given-names></name><name><surname>Ghiabi</surname><given-names>Pegah</given-names></name><name><surname>Hajian</surname><given-names>Taraneh</given-names></name><name><surname>Loppnau</surname><given-names>Peter</given-names></name><name><surname>Bolotokova</surname><given-names>Albina</given-names></name><etal/></person-group><article-title>Probing the sam binding site of sars-cov-2 nsp14 in vitro using sam competitive inhibitors guides developing selective bisubstrate inhibitors</article-title><source>SLAS DISCOVERY: Advancing the Science of Drug Discovery</source><year>2021</year><volume>26</volume><issue>9</issue><fpage>1200</fpage><lpage>1211</lpage><pub-id pub-id-type="pmcid">PMC8458670</pub-id><pub-id pub-id-type="pmid">34192965</pub-id><pub-id pub-id-type="doi">10.1177/24725552211026261</pub-id></element-citation></ref><ref id="R22"><label>[22]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klima</surname><given-names>Martin</given-names></name><name><surname>Yazdi</surname><given-names>Aliakbar Khalili</given-names></name><name><surname>Li</surname><given-names>Fengling</given-names></name><name><surname>Chau</surname><given-names>Irene</given-names></name><name><surname>Hajian</surname><given-names>Taraneh</given-names></name><name><surname>Bolotokova</surname><given-names>Albina</given-names></name><name><surname>Kaniskan</surname><given-names>H Ümit</given-names></name><name><surname>Han</surname><given-names>Yulin</given-names></name><name><surname>Wang</surname><given-names>Ke</given-names></name><name><surname>Li</surname><given-names>Deyao</given-names></name><etal/></person-group><article-title>Crystal structure of sars-cov-2 nsp10–nsp16 in complex with small molecule inhibitors, ss148 and wz16</article-title><source>Protein Science</source><year>2022</year><volume>31</volume><issue>9</issue><elocation-id>e4395</elocation-id><pub-id pub-id-type="pmcid">PMC9375521</pub-id><pub-id pub-id-type="pmid">36040262</pub-id><pub-id pub-id-type="doi">10.1002/pro.4395</pub-id></element-citation></ref><ref id="R23"><label>[23]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenone</surname><given-names>Monica</given-names></name><name><surname>Dančík</surname><given-names>Vlado</given-names></name><name><surname>Wagner</surname><given-names>Bridget K</given-names></name><name><surname>Clemons</surname><given-names>Paul A</given-names></name></person-group><article-title>Target identification and mechanism of action in chemical biology and drug discovery</article-title><source>Nature chemical biology</source><year>2013</year><volume>9</volume><issue>4</issue><fpage>232</fpage><lpage>240</lpage><pub-id pub-id-type="pmcid">PMC5543995</pub-id><pub-id pub-id-type="pmid">23508189</pub-id><pub-id pub-id-type="doi">10.1038/nchembio.1199</pub-id></element-citation></ref><ref id="R24"><label>[24]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Shunzhou</given-names></name><name><surname>Bhati</surname><given-names>Agastya P</given-names></name><name><surname>Zasada</surname><given-names>Stefan J</given-names></name><name><surname>Coveney</surname><given-names>Peter V</given-names></name></person-group><article-title>Rapid, accurate, precise and reproducible ligand–protein binding free energy prediction</article-title><source>Interface Focus</source><year>2020</year><volume>10</volume><issue>6</issue><elocation-id>20200007</elocation-id><pub-id pub-id-type="pmcid">PMC7653346</pub-id><pub-id pub-id-type="pmid">33178418</pub-id><pub-id pub-id-type="doi">10.1098/rsfs.2020.0007</pub-id></element-citation></ref><ref id="R25"><label>[25]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friesner</surname><given-names>Richard A</given-names></name><name><surname>Banks</surname><given-names>Jay L</given-names></name><name><surname>Murphy</surname><given-names>Robert B</given-names></name><name><surname>Halgren</surname><given-names>Thomas A</given-names></name><name><surname>Klicic</surname><given-names>Jasna J</given-names></name><name><surname>Mainz</surname><given-names>Daniel T</given-names></name><name><surname>Repasky</surname><given-names>Matthew P</given-names></name><name><surname>Knoll</surname><given-names>Eric H</given-names></name><name><surname>Shelley</surname><given-names>Mee</given-names></name><name><surname>Perry</surname><given-names>Jason K</given-names></name><etal/></person-group><article-title>Glide: a new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</article-title><source>Journal of medicinal chemistry</source><year>2004</year><volume>47</volume><issue>7</issue><fpage>1739</fpage><lpage>1749</lpage><pub-id pub-id-type="pmid">15027865</pub-id></element-citation></ref><ref id="R26"><label>[26]</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Homola</surname><given-names>Jiří</given-names></name><name><surname>Piliarik</surname><given-names>Marek</given-names></name></person-group><source>Surface plasmon resonance (SPR) sensors</source><year>2006</year><publisher-name>Springer</publisher-name><pub-id pub-id-type="pmid">19770865</pub-id></element-citation></ref><ref id="R27"><label>[27]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varshney</surname><given-names>Dhaval</given-names></name><name><surname>Petit</surname><given-names>Alain-Pierre</given-names></name><name><surname>Bueren-Calabuig</surname><given-names>Juan A</given-names></name><name><surname>Jansen</surname><given-names>Chimed</given-names></name><name><surname>Fletcher</surname><given-names>Dan A</given-names></name><name><surname>Peggie</surname><given-names>Mark</given-names></name><name><surname>Weidlich</surname><given-names>Simone</given-names></name><name><surname>Scullion</surname><given-names>Paul</given-names></name><name><surname>Pisliakov</surname><given-names>Andrei V</given-names></name><name><surname>Cowling</surname><given-names>Victoria H</given-names></name></person-group><article-title>Molecular basis of rna guanine-7 methyltransferase (rnmt) activation by ram</article-title><source>Nucleic acids research</source><year>2016</year><volume>44</volume><issue>21</issue><fpage>10423</fpage><lpage>10436</lpage><pub-id pub-id-type="pmcid">PMC5137418</pub-id><pub-id pub-id-type="pmid">27422871</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkw637</pub-id></element-citation></ref><ref id="R28"><label>[28]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>Kanishk</given-names></name><name><surname>Clarke</surname><given-names>Steven G</given-names></name></person-group><article-title>Prmt7 as a unique member of the protein arginine methyltransferase family: A review</article-title><source>Archives of biochemistry and biophysics</source><year>2019</year><volume>665</volume><fpage>36</fpage><lpage>45</lpage><comment>2018</comment><pub-id pub-id-type="pmcid">PMC6461449</pub-id><pub-id pub-id-type="pmid">30802433</pub-id><pub-id pub-id-type="doi">10.1016/j.abb.2019.02.014</pub-id></element-citation></ref><ref id="R29"><label>[29]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Delft</surname><given-names>Annette</given-names></name><name><surname>Hall</surname><given-names>Matthew D</given-names></name><name><surname>Kwong</surname><given-names>Ann D</given-names></name><name><surname>Purcell</surname><given-names>Lisa A</given-names></name><name><surname>Saikatendu</surname><given-names>Kumar Singh</given-names></name><name><surname>Schmitz</surname><given-names>Uli</given-names></name><name><surname>Tallarico</surname><given-names>John A</given-names></name><name><surname>Lee</surname><given-names>Alpha A</given-names></name></person-group><article-title>Accelerating antiviral drug discovery: lessons from covid-19</article-title><source>Nature Reviews Drug Discovery</source><year>2023</year><fpage>1</fpage><lpage>19</lpage></element-citation></ref><ref id="R30"><label>[30]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>Sharmistha</given-names></name><name><surname>Sif</surname><given-names>Saïd</given-names></name></person-group><article-title>Interplay between chromatin remodelers and protein arginine methyltransferases</article-title><source>Journal of cellular physiology</source><year>2007</year><volume>213</volume><issue>2</issue><fpage>306</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">17708529</pub-id></element-citation></ref><ref id="R31"><label>[31]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pande</surname><given-names>Vijay S</given-names></name><name><surname>Beauchamp</surname><given-names>Kyle</given-names></name><name><surname>Bowman</surname><given-names>Gregory R</given-names></name></person-group><article-title>Everything you wanted to know about markov state models but were afraid to ask</article-title><source>Methods</source><year>2010</year><volume>52</volume><issue>1</issue><fpage>99</fpage><lpage>105</lpage><pub-id pub-id-type="pmcid">PMC2933958</pub-id><pub-id pub-id-type="pmid">20570730</pub-id><pub-id pub-id-type="doi">10.1016/j.ymeth.2010.06.002</pub-id></element-citation></ref><ref id="R32"><label>[32]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naritomi</surname><given-names>Yusuke</given-names></name><name><surname>Fuchigami</surname><given-names>Sotaro</given-names></name></person-group><article-title>Slow dynamics in protein fluctuations revealed by time-structure based independent component analysis: the case of domain motions</article-title><source>The Journal of chemical physics</source><year>2011</year><volume>134</volume><issue>6</issue><pub-id pub-id-type="pmid">21322734</pub-id></element-citation></ref><ref id="R33"><label>[33]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartigan</surname><given-names>IA</given-names></name><name><surname>Algoritm</surname><given-names>AS</given-names></name></person-group><article-title>136: A k-means clustering algorithm/ja hartigan, ma wong</article-title><source>Journal of the Royal Statistical Society Series C (Applied Statistic)</source><year>1979</year><volume>28</volume><issue>1</issue><fpage>100</fpage><lpage>108</lpage></element-citation></ref><ref id="R34"><label>[34]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>Jeffrey R</given-names></name><name><surname>Lee</surname><given-names>Christopher T</given-names></name><name><surname>Durrant</surname><given-names>Jacob D</given-names></name><name><surname>Malmstrom</surname><given-names>Robert D</given-names></name><name><surname>Feher</surname><given-names>Victoria A</given-names></name><name><surname>Amaro</surname><given-names>Rommie E</given-names></name></person-group><article-title>Emerging computational methods for the rational discovery of allosteric drugs</article-title><source>Chemical reviews</source><year>2016</year><volume>116</volume><issue>11</issue><fpage>6370</fpage><lpage>6390</lpage><pub-id pub-id-type="pmcid">PMC4901368</pub-id><pub-id pub-id-type="pmid">27074285</pub-id><pub-id pub-id-type="doi">10.1021/acs.chemrev.5b00631</pub-id></element-citation></ref><ref id="R35"><label>[35]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>PR</given-names></name><name><surname>Craik</surname><given-names>DJ</given-names></name><name><surname>Martin</surname><given-names>JL</given-names></name></person-group><article-title>Functional group contributions to drug-receptor interactions</article-title><source>Journal of medicinal chemistry</source><year>1984</year><volume>27</volume><issue>12</issue><fpage>1648</fpage><lpage>1657</lpage><pub-id pub-id-type="pmid">6094812</pub-id></element-citation></ref><ref id="R36"><label>[36]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teague</surname><given-names>Simon J</given-names></name></person-group><article-title>Implications of protein flexibility for drug discovery</article-title><source>Nature reviews Drug discovery</source><year>2003</year><volume>2</volume><issue>7</issue><fpage>527</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">12838268</pub-id></element-citation></ref><ref id="R37"><label>[37]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Huameng</given-names></name><name><surname>Li</surname><given-names>Chenglong</given-names></name></person-group><article-title>Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein</article-title><source>Journal of computational chemistry</source><year>2010</year><volume>31</volume><issue>10</issue><fpage>2014</fpage><lpage>2022</lpage><pub-id pub-id-type="pmid">20166125</pub-id></element-citation></ref><ref id="R38"><label>[38]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kottur</surname><given-names>Jithesh</given-names></name><name><surname>Rechkoblit</surname><given-names>Olga</given-names></name><name><surname>Quintana-Feliciano</surname><given-names>Richard</given-names></name><name><surname>Sciaky</surname><given-names>Daniela</given-names></name><name><surname>Aggarwal</surname><given-names>Aneel K</given-names></name></person-group><article-title>High-resolution structures of the sars-cov-2 n7-methyltransferase inform therapeutic development</article-title><source>Nature Structural &amp; Molecular Biology</source><year>2022</year><volume>29</volume><issue>9</issue><fpage>850</fpage><lpage>853</lpage><pub-id pub-id-type="pmcid">PMC10388636</pub-id><pub-id pub-id-type="pmid">36075969</pub-id><pub-id pub-id-type="doi">10.1038/s41594-022-00828-1</pub-id></element-citation></ref><ref id="R39"><label>[39]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Chang</given-names></name><name><surname>Shi</surname><given-names>Wei</given-names></name><name><surname>Becker</surname><given-names>Scott T</given-names></name><name><surname>Schatz</surname><given-names>David G</given-names></name><name><surname>Liu</surname><given-names>Bin</given-names></name><name><surname>Yang</surname><given-names>Yang</given-names></name></person-group><article-title>Structural basis of mismatch recognition by a sars-cov-2 proofreading enzyme</article-title><source>Science</source><year>2021</year><volume>373</volume><issue>6559</issue><fpage>1142</fpage><lpage>1146</lpage><pub-id pub-id-type="pmcid">PMC9836006</pub-id><pub-id pub-id-type="pmid">34315827</pub-id><pub-id pub-id-type="doi">10.1126/science.abi9310</pub-id></element-citation></ref><ref id="R40"><label>[40]</label><element-citation publication-type="book"><collab>Schr odinger Release</collab><chapter-title>2: Protein preparation wizard, epik, schrödinger, llc, new york, ny, 2021</chapter-title><source>Impact</source><year>2021</year><publisher-name>Schrödinger, LLC</publisher-name><publisher-loc>New York, NY</publisher-loc></element-citation></ref><ref id="R41"><label>[41]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Yuanyuan</given-names></name><name><surname>Wu</surname><given-names>Lijie</given-names></name><name><surname>Shaw</surname><given-names>Neil</given-names></name><name><surname>Gao</surname><given-names>Yan</given-names></name><name><surname>Wang</surname><given-names>Jin</given-names></name><name><surname>Sun</surname><given-names>Yuna</given-names></name><name><surname>Lou</surname><given-names>Zhiyong</given-names></name><name><surname>Yan</surname><given-names>Liming</given-names></name><name><surname>Zhang</surname><given-names>Rongguang</given-names></name><name><surname>Rao</surname><given-names>Zihe</given-names></name></person-group><article-title>Structural basis and functional analysis of the sars coronavirus nsp14–nsp10 complex</article-title><source>Proceedings of the National Academy of Sciences</source><year>2015</year><volume>112</volume><issue>30</issue><fpage>9436</fpage><lpage>9441</lpage><pub-id pub-id-type="pmcid">PMC4522806</pub-id><pub-id pub-id-type="pmid">26159422</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1508686112</pub-id></element-citation></ref><ref id="R42"><label>[42]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Chao</given-names></name><name><surname>Wu</surname><given-names>Chuanjie</given-names></name><name><surname>Ghoreishi</surname><given-names>Delaram</given-names></name><name><surname>Chen</surname><given-names>Wei</given-names></name><name><surname>Wang</surname><given-names>Lingle</given-names></name><name><surname>Damm</surname><given-names>Wolfgang</given-names></name><name><surname>Ross</surname><given-names>Gregory A</given-names></name><name><surname>Dahlgren</surname><given-names>Markus K</given-names></name><name><surname>Russell</surname><given-names>Ellery</given-names></name><name><surname>Von Bargen</surname><given-names>Christopher D</given-names></name><etal/></person-group><article-title>Opls4: Improving force field accuracy on challenging regimes of chemical space</article-title><source>Journal of chemical theory and computation</source><year>2021</year><volume>17</volume><issue>7</issue><fpage>4291</fpage><lpage>4300</lpage><pub-id pub-id-type="pmid">34096718</pub-id></element-citation></ref><ref id="R43"><label>[43]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhossary</surname><given-names>Amr</given-names></name><name><surname>Handoko</surname><given-names>Stephanus Daniel</given-names></name><name><surname>Mu</surname><given-names>Yuguang</given-names></name><name><surname>Kwoh</surname><given-names>Chee-Keong</given-names></name></person-group><article-title>Fast, accurate, and reliable molecular docking with quickvina 2</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><issue>13</issue><fpage>2214</fpage><lpage>2216</lpage><pub-id pub-id-type="pmid">25717194</pub-id></element-citation></ref><ref id="R44"><label>[44]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koes</surname><given-names>David Ryan</given-names></name><name><surname>Baumgartner</surname><given-names>Matthew P</given-names></name><name><surname>Camacho</surname><given-names>Carlos J</given-names></name></person-group><article-title>Lessons learned in empirical scoring with smina from the csar 2011 benchmarking exercise</article-title><source>Journal of chemical information and modeling</source><year>2013</year><volume>53</volume><issue>8</issue><fpage>1893</fpage><lpage>1904</lpage><pub-id pub-id-type="pmcid">PMC3726561</pub-id><pub-id pub-id-type="pmid">23379370</pub-id><pub-id pub-id-type="doi">10.1021/ci300604z</pub-id></element-citation></ref><ref id="R45"><label>[45]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>David</given-names></name><name><surname>Hahn</surname><given-names>Mathew</given-names></name></person-group><article-title>Extended-connectivity fingerprints</article-title><source>Journal of chemical information and modeling</source><year>2010</year><volume>50</volume><issue>5</issue><fpage>742</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">20426451</pub-id></element-citation></ref><ref id="R46"><label>[46]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>James A</given-names></name><name><surname>Martinez</surname><given-names>Carmenza</given-names></name><name><surname>Kasavajhala</surname><given-names>Koushik</given-names></name><name><surname>Wickstrom</surname><given-names>Lauren</given-names></name><name><surname>Hauser</surname><given-names>Kevin E</given-names></name><name><surname>Simmerling</surname><given-names>Carlos</given-names></name></person-group><article-title>ff14sb: improving the accuracy of protein side chain and backbone parameters from ff99sb</article-title><source>Journal of chemical theory and computation</source><year>2015</year><volume>11</volume><issue>8</issue><fpage>3696</fpage><lpage>3713</lpage><pub-id pub-id-type="pmcid">PMC4821407</pub-id><pub-id pub-id-type="pmid">26574453</pub-id><pub-id pub-id-type="doi">10.1021/acs.jctc.5b00255</pub-id></element-citation></ref><ref id="R47"><label>[47]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Junmei</given-names></name><name><surname>Wolf</surname><given-names>Romain M</given-names></name><name><surname>Caldwell</surname><given-names>James W</given-names></name><name><surname>Kollman</surname><given-names>Peter A</given-names></name><name><surname>Case</surname><given-names>David A</given-names></name></person-group><article-title>Development and testing of a general amber force field</article-title><source>Journal of computational chemistry</source><year>2004</year><volume>25</volume><issue>9</issue><fpage>1157</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">15116359</pub-id></element-citation></ref><ref id="R48"><label>[48]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Junmei</given-names></name><name><surname>Wang</surname><given-names>Wei</given-names></name><name><surname>Kollman</surname><given-names>Peter A</given-names></name><name><surname>Case</surname><given-names>David A</given-names></name></person-group><article-title>Antechamber: an accessory software package for molecular mechanical calculations</article-title><source>J Am Chem Soc</source><year>2001</year><volume>222</volume><issue>1</issue></element-citation></ref><ref id="R49"><label>[49]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaus</surname><given-names>Joseph W</given-names></name><name><surname>Pierce</surname><given-names>Levi T</given-names></name><name><surname>Walker</surname><given-names>Ross C</given-names></name><name><surname>McCammon</surname><given-names>J Andrew</given-names></name></person-group><article-title>Improving the efficiency of free energy calculations in the amber molecular dynamics package</article-title><source>Journal of chemical theory and computation</source><year>2013</year><volume>9</volume><issue>9</issue><fpage>4131</fpage><lpage>4139</lpage><pub-id pub-id-type="pmcid">PMC3811123</pub-id><pub-id pub-id-type="pmid">24185531</pub-id><pub-id pub-id-type="doi">10.1021/ct400340s</pub-id></element-citation></ref><ref id="R50"><label>[50]</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Case</surname><given-names>David A</given-names></name><name><surname>Aktulga</surname><given-names>H Metin</given-names></name><name><surname>Belfon</surname><given-names>Kellon</given-names></name><name><surname>Ben-Shalom</surname><given-names>Ido</given-names></name><name><surname>Brozell</surname><given-names>Scott R</given-names></name><name><surname>Cerutti</surname><given-names>David S</given-names></name><name><surname>Cheatham</surname><given-names>Thomas E</given-names><suffix>III</suffix></name><name><surname>Cruzeiro</surname><given-names>Vinícius Wilian D</given-names></name><name><surname>Darden</surname><given-names>Tom A</given-names></name><name><surname>Duke</surname><given-names>Robert E</given-names></name><etal/></person-group><source>Amber 2021</source><year>2021</year><publisher-name>University of California</publisher-name><publisher-loc>San Francisco</publisher-loc></element-citation></ref><ref id="R51"><label>[51]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>Uwe</given-names></name><name><surname>Förster</surname><given-names>Ronald</given-names></name><name><surname>Hellmig</surname><given-names>Michael</given-names></name><name><surname>Huschmann</surname><given-names>Franziska U</given-names></name><name><surname>Kastner</surname><given-names>Alexandra</given-names></name><name><surname>Malecki</surname><given-names>Piotr</given-names></name><name><surname>Pühringer</surname><given-names>Sandra</given-names></name><name><surname>Röwer</surname><given-names>Martin</given-names></name><name><surname>Sparta</surname><given-names>Karine</given-names></name><name><surname>Steffien</surname><given-names>Michael</given-names></name><etal/></person-group><article-title>The macromolecular crystallography beamlines at bessy ii of the helmholtzzentrum berlin: Current status and perspectives</article-title><source>The European Physical Journal Plus</source><year>2015</year><volume>130</volume><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="R52"><label>[52]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname><given-names>Wolfgang</given-names></name></person-group><article-title>xds</article-title><source>Acta Crystallographica Section D: Biological Crystallography</source><year>2010</year><volume>66</volume><issue>2</issue><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="pmcid">PMC2815665</pub-id><pub-id pub-id-type="pmid">20124692</pub-id><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id></element-citation></ref><ref id="R53"><label>[53]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>Airlie J</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>Ralf W</given-names></name><name><surname>Adams</surname><given-names>Paul D</given-names></name><name><surname>Winn</surname><given-names>Martyn D</given-names></name><name><surname>Storoni</surname><given-names>Laurent C</given-names></name><name><surname>Read</surname><given-names>Randy J</given-names></name></person-group><article-title>Phaser crystallographic software</article-title><source>Journal of applied crystallography</source><year>2007</year><volume>40</volume><issue>4</issue><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="pmcid">PMC2483472</pub-id><pub-id pub-id-type="pmid">19461840</pub-id><pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id></element-citation></ref><ref id="R54"><label>[54]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebschner</surname><given-names>Dorothee</given-names></name><name><surname>Afonine</surname><given-names>Pavel V</given-names></name><name><surname>Baker</surname><given-names>Matthew L</given-names></name><name><surname>Bunkóczi</surname><given-names>Gábor</given-names></name><name><surname>Chen</surname><given-names>Vincent B</given-names></name><name><surname>Croll</surname><given-names>Tristan I</given-names></name><name><surname>Hintze</surname><given-names>Bradley</given-names></name><name><surname>Hung</surname><given-names>L-W</given-names></name><name><surname>Jain</surname><given-names>Swati</given-names></name><name><surname>McCoy</surname><given-names>Airlie J</given-names></name><etal/></person-group><article-title>Macromolecular structure determination using x-rays, neutrons and electrons: recent developments in phenix</article-title><source>Acta Crystallographica Section D: Structural Biology</source><year>2019</year><volume>75</volume><issue>10</issue><fpage>861</fpage><lpage>877</lpage><pub-id pub-id-type="pmcid">PMC6778852</pub-id><pub-id pub-id-type="pmid">31588918</pub-id><pub-id pub-id-type="doi">10.1107/S2059798319011471</pub-id></element-citation></ref><ref id="R55"><label>[55]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afonine</surname><given-names>Pavel V</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>Ralf W</given-names></name><name><surname>Echols</surname><given-names>Nathaniel</given-names></name><name><surname>Headd</surname><given-names>Jeffrey J</given-names></name><name><surname>Moriarty</surname><given-names>Nigel W</given-names></name><name><surname>Mustyakimov</surname><given-names>Marat</given-names></name><name><surname>Terwilliger</surname><given-names>Thomas C</given-names></name><name><surname>Urzhumtsev</surname><given-names>Alexandre</given-names></name><name><surname>Zwart</surname><given-names>Peter H</given-names></name><name><surname>Adams</surname><given-names>Paul D</given-names></name></person-group><article-title>Towards automated crystallographic structure refinement with phenix. refine</article-title><source>Acta Crystallographica Section D: Biological Crystallography</source><year>2012</year><volume>68</volume><issue>4</issue><fpage>352</fpage><lpage>367</lpage><pub-id pub-id-type="pmcid">PMC3322595</pub-id><pub-id pub-id-type="pmid">22505256</pub-id><pub-id pub-id-type="doi">10.1107/S0907444912001308</pub-id></element-citation></ref><ref id="R56"><label>[56]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>Paul</given-names></name><name><surname>Cowtan</surname><given-names>Kevin</given-names></name></person-group><article-title>Coot: model-building tools for molecular graphics</article-title><source>Acta crystallographica section D: biological crystallography</source><year>2004</year><volume>60</volume><issue>12</issue><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="pmid">15572765</pub-id></element-citation></ref><ref id="R57"><label>[57]</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>DeLano</surname><given-names>Warren L</given-names></name></person-group><source>The pymol molecular graphics system</source><year>2002</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.pymol.org/">http://www.pymol.org/</ext-link></comment></element-citation></ref><ref id="R58"><label>[58]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>Sunhwan</given-names></name><name><surname>Kim</surname><given-names>Taehoon</given-names></name><name><surname>Iyer</surname><given-names>Vidyashankara G</given-names></name><name><surname>Im</surname><given-names>Wonpil</given-names></name></person-group><article-title>Charmm-gui: a web-based graphical user interface for charmm</article-title><source>Journal of computational chemistry</source><year>2008</year><volume>29</volume><issue>11</issue><fpage>1859</fpage><lpage>1865</lpage><pub-id pub-id-type="pmid">18351591</pub-id></element-citation></ref><ref id="R59"><label>[59]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Jing</given-names></name><name><surname>Rauscher</surname><given-names>Sarah</given-names></name><name><surname>Nawrocki</surname><given-names>Grzegorz</given-names></name><name><surname>Ran</surname><given-names>Ting</given-names></name><name><surname>Feig</surname><given-names>Michael</given-names></name><name><surname>De Groot</surname><given-names>Bert L</given-names></name><name><surname>Grubmüller</surname><given-names>Helmut</given-names></name><name><surname>MacKerell</surname><given-names>Alexander D</given-names><suffix>Jr</suffix></name></person-group><article-title>Charmm36m: an improved force field for folded and intrinsically disordered proteins</article-title><source>Nature methods</source><year>2017</year><volume>14</volume><issue>1</issue><fpage>71</fpage><lpage>73</lpage><pub-id pub-id-type="pmcid">PMC5199616</pub-id><pub-id pub-id-type="pmid">27819658</pub-id><pub-id pub-id-type="doi">10.1038/nmeth.4067</pub-id></element-citation></ref><ref id="R60"><label>[60]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Der Spoel</surname><given-names>David</given-names></name><name><surname>Lindahl</surname><given-names>Erik</given-names></name><name><surname>Hess</surname><given-names>Berk</given-names></name><name><surname>Groenhof</surname><given-names>Gerrit</given-names></name><name><surname>Mark</surname><given-names>Alan E</given-names></name><name><surname>Berendsen</surname><given-names>Herman JC</given-names></name></person-group><article-title>Gromacs: fast, flexible, and free</article-title><source>Journal of computational chemistry</source><year>2005</year><volume>26</volume><issue>16</issue><fpage>1701</fpage><lpage>1718</lpage><pub-id pub-id-type="pmid">16211538</pub-id></element-citation></ref><ref id="R61"><label>[61]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>Shuichi</given-names></name><name><surname>Kollman</surname><given-names>Peter A</given-names></name></person-group><article-title>Settle: An analytical version of the shake and rattle algorithm for rigid water models</article-title><source>Journal of computational chemistry</source><year>1992</year><volume>13</volume><issue>8</issue><fpage>952</fpage><lpage>962</lpage></element-citation></ref><ref id="R62"><label>[62]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanommeslaeghe</surname><given-names>Kenno</given-names></name><name><surname>MacKerell</surname><given-names>Alexander D</given-names><suffix>Jr</suffix></name></person-group><article-title>Automation of the charmm general force field (cgenff) i: bond perception and atom typing</article-title><source>Journal of chemical information and modeling</source><year>2012</year><volume>52</volume><issue>12</issue><fpage>3144</fpage><lpage>3154</lpage><pub-id pub-id-type="pmcid">PMC3528824</pub-id><pub-id pub-id-type="pmid">23146088</pub-id><pub-id pub-id-type="doi">10.1021/ci300363c</pub-id></element-citation></ref><ref id="R63"><label>[63]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGibbon</surname><given-names>Robert T</given-names></name><name><surname>Beauchamp</surname><given-names>Kyle A</given-names></name><name><surname>Harrigan</surname><given-names>Matthew P</given-names></name><name><surname>Klein</surname><given-names>Christoph</given-names></name><name><surname>Swails</surname><given-names>Jason M</given-names></name><name><surname>Hernández</surname><given-names>Carlos X</given-names></name><name><surname>Schwantes</surname><given-names>Christian R</given-names></name><name><surname>Wang</surname><given-names>Lee-Ping</given-names></name><name><surname>Lane</surname><given-names>Thomas J</given-names></name><name><surname>Pande</surname><given-names>Vijay S</given-names></name></person-group><article-title>Mdtraj: a modern open library for the analysis of molecular dynamics trajectories</article-title><source>Biophysical journal</source><year>2015</year><volume>109</volume><issue>8</issue><fpage>1528</fpage><lpage>1532</lpage><pub-id pub-id-type="pmcid">PMC4623899</pub-id><pub-id pub-id-type="pmid">26488642</pub-id><pub-id pub-id-type="doi">10.1016/j.bpj.2015.08.015</pub-id></element-citation></ref><ref id="R64"><label>[64]</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spurr</surname><given-names>Sophie S</given-names></name><name><surname>Bayle</surname><given-names>Elliott D</given-names></name><name><surname>Yu</surname><given-names>Wenyu</given-names></name><name><surname>Li</surname><given-names>Fengling</given-names></name><name><surname>Tempel</surname><given-names>Wolfram</given-names></name><name><surname>Vedadi</surname><given-names>Masoud</given-names></name><name><surname>Schapira</surname><given-names>Matthieu</given-names></name><name><surname>Fish</surname><given-names>Paul V</given-names></name></person-group><article-title>New small molecule inhibitors of histone methyl transferase dot1l with a nitrile as a non-traditional replacement for heavy halogen atoms</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><year>2016</year><volume>26</volume><issue>18</issue><fpage>4518</fpage><lpage>4522</lpage><pub-id pub-id-type="pmid">27485386</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><title>Computational pipeline for identification of lead compounds.</title><p><bold>(A)</bold> Depiction of the SARS-CoV-2 nsp14-MTase Protein Target and Computational Workflow. The protein target (PDB:7N0B), in complex with nsp10, is employed for the modeling process. The highlighted binding site (indicated in orange) within the MTase domain acts as the docking site for molecular interactions. <bold>(B)</bold> The computational workflow powered by VirtualFlow Unity (VFU), which processes SMILES strings from the NCI Open Compound Collections as input. The procedure includes desalting, neutralizing, and generating stereoisomers of the input molecule. Subsequently, all processed molecules from the database undergo docking onto the binding site using Glide-SP. The output docked compounds are ranked based on their docking scores, with the top 1,000 subjected to a more precise scoring algorithm, Glide-XP. A diverse subset of 100 molecules is chosen for an advanced binding energy estimation using Molecular Mechanics Generalized Born Surface Area (MM/GBSA). The top 40 of these compounds, ranked by their binding potential, are then selected for experimental evaluation. <bold>(C)</bold> The selected top-40 compounds are initially assessed using a radioactivity-based assay, yielding seven compounds with promising results. Subsequently, a detailed binding study is performed with the top-5 compounds utilizing surface plasmon resonance. The in-vivo evaluation follows, focusing on the top-2 compounds with SARS-CoV-2 infected Calu-3 cells. Ultimately, the compound identified as the most promising is re-tested after a custom synthesis process, leading not only to improved purity, but also confirming the identification of a lead compound.</p></caption><graphic xlink:href="EMS189149-f001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><title>Interaction Analysis of Identified MTase Inhibitors.</title><p>Presented are the 2D structural diagrams of experimentally validated compounds (top-3) found to inhibit nsp14 MTase activity. Alongside these structures, their respective 2D interaction diagrams, derived from docking studies, are displayed. The figure also depicts the putative 3D poses these compounds assume within nsp14’s lateral cavity.</p></caption><graphic xlink:href="EMS189149-f002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><title>Inhibition of nsp14 MTase activity by NSC620333.</title><p><bold>(A)</bold> The IC<sub>50</sub> value was determined for NSC620333 at <italic>K</italic><sub><italic>m</italic></sub> of both SAM and RNA substrates (5.3 ± 1.0 <italic>μM</italic>, Hill Slope: − 0.9). The mechanism of action (MOA) of NSC620333 was also determined by IC<sub>50</sub> determination for NSC620333 at <bold>(B)</bold> varying concentrations of SAM (from 0.15 to 2.5 <italic>μM</italic>) at fixed concentration of RNA substrate (0.25 <italic>μM</italic>, 5x <italic>K</italic><sub><italic>m</italic></sub>) and <bold>(C)</bold> varying concentrations of RNA substrate (from 31 to 500 <italic>nM</italic>) at fixed concentration of SAM (1.25 <italic>μM</italic>, 5x <italic>K<sub>m</sub></italic>). All values are presented as mean <italic>±</italic> standard deviation of three independent experiments (<italic>n</italic> = 3). NSC620333 is a SAM competitive nsp14 inhibitor (B), and noncompetitive with respect to RNA substrate (C).</p></caption><graphic xlink:href="EMS189149-f003"/></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><title>Protein Conformation and Interaction Dynamics from Molecular Simulations.</title><p><bold>(A)</bold> Bar charts presenting the mean displacement (expressed in angstroms) of amino acid residues within a 5-angstrom vicinity of the binding pocket, derived from 1-microsecond molecular dynamics simulations conducted at a stable temperature of 303.15 <italic>K</italic>. The error bars indicate the standard deviation of the mean, based on five distinct simulation runs. <bold>(B)</bold> (Left) A graphical representation of the most notable conformational shifts in nsp10, as determined through a series of MD-simulations involving nsp10-14, with only minor changes due to the consistent stability of the nsp10-nsp14 interaction. (Middle) Select residues at the nsp10 binding interface making the most significant contribution to the interaction with nsp16. (Right) Breakdown of individual residues of nsp10 with the highest free energy contributions (kcal/mol) to the overall binding free energy estimation of nsp10-14 interactions; the average contribution from a single residue is indicated by a dotted line.</p></caption><graphic xlink:href="EMS189149-f004"/></fig><fig id="F5" position="float"><label>Fig. 5</label><caption><title>Analyzing Nsp14-nsp10 Conformational Variability through tICA Projections Influenced by Coordination Complexes.</title><p>This figure delineates the conformational differences in the nsp10-nsp14 complex under ion-devoid and ion-inclusive states, emphasizing structures from four representative cluster centers with high variance. Trajectories were derived from independent runs between 200 ns <italic>−</italic> 1 <italic>μ</italic>s, focusing on pairwise distances between alternating backbone <italic>α</italic>-carbons to determine simulation features and enhance the sampling of diverse conformations.</p></caption><graphic xlink:href="EMS189149-f005"/></fig><fig id="F6" position="float"><label>Fig. 6</label><caption><title>tICA Decomposition and Representative Structures of NSC620333 Alternative Binding Poses.</title><p>The figure illustrates the tICA decomposition and associated structures of various binding poses of NSC620333, derived from a combination of trajectories that incorporate unbiased molecular dynamics simulations. The trajectories were featurized by calculating pairwise distances between heavy ligand atoms and backbone <italic>α</italic>-carbons of key residues surrounding the binding site. Cluster 2 illustrates the prevalent metastable binding mode observed, while Cluster 0 and Cluster 6 depict twisted and inward binding modes, respectively.</p></caption><graphic xlink:href="EMS189149-f006"/></fig><fig id="F7" position="float"><label>Fig. 7</label><caption><title>Crystal structure of nsp14 MTase in complex with SS148.</title><p><bold>(a)</bold>, Overall view of the nsp14/SS148 complex. The protein backbone of the nsp14 MTase domain is shown in cartoon representation and colored in light blue. The SS148 ligand is shown in stick representation and colored according to elements: carbon, magenta; nitrogen, blue; oxygen, red; sulfur, yellow. The unbiased Fo-Fc omit map contoured at 2s is shown around the SS148 ligand. The TELSAM crystallization tag N-terminally fused to the nsp14 MTase domain is not shown. <bold>(b)</bold>, Detailed view of the SS148 ligand binding site. The SS148 ligand and side chains of selected nsp14 amino acid residues are shown in stick representation, with carbon atoms colored according to the protein assignment and other elements colored as in (a). Water molecules are presented as red spheres; hydrogen atoms are not shown. Selected hydrogen bonds involved in the nsp14–SS148 interaction are depicted as dashed black lines. <bold>(c)</bold>, SS148 ligand binding site with nsp14 shown in surface representation. The nitrile group binding groove on the surface of nsp14 potentially accepting larger substituents is highlighted with a red dashed circle. <bold>(d)</bold>, Structural alignment of the SS148 binding sites of SARS-CoV-2 N7-MTase nsp14 and 2’-O-MTase nsp16. Protein backbones are shown in cartoon representation, while SS148 and side chains of selected residues are shown in stick representation. The carbon atoms of the nsp14/SS148 and nsp16/SS148 complexes are depicted in light blue and yellow, respectively; other elements are colored as in (a).</p></caption><graphic xlink:href="EMS189149-f007"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table I</label><caption><title>High-throughput Screening Results of top 40 Compounds obtained for the Inhibition of nsp14 Methyltransferase (MTase) Activity.</title><p>This table summarizes the inhibitory effects of the top 40 compounds on nsp14 MTase activity as assessed by high-throughput screening. For each compound, data from two replicate experiments are included, revealing the inhibition percentages at a compound concentration of 100<italic>μ</italic>M. The IC<sub>50</sub> values, indicating the concentration at which half-maximal inhibition is achieved, are reported for the most promising compounds. The table also provides the observed quenching effects of each compound. The term “ND” indicates that the value is not determined.</p></caption><table frame="box" rules="cols"><thead><tr><th align="center" valign="middle">Compound</th><th align="center" valign="middle" colspan="2">nspl4 Inhibition % (100<italic>μ</italic>M)</th><th align="center" valign="middle">IC<sub>50</sub> (<italic>μ</italic>M)</th><th align="center" valign="middle">Quenching effect %</th></tr><tr><th align="center" valign="middle"/><th align="center" valign="middle">Exp 1</th><th align="center" valign="middle">Exp 2</th><th align="center" valign="middle"/><th align="center" valign="middle"/></tr></thead><tbody><tr><td align="center" valign="middle">NSC76988</td><td align="center" valign="middle">100</td><td align="center" valign="middle">99</td><td align="center" valign="middle">6</td><td align="center" valign="middle">8</td></tr><tr><td align="center" valign="middle">NSC620333</td><td align="center" valign="middle">100</td><td align="center" valign="middle">99</td><td align="center" valign="middle">5</td><td align="center" valign="middle">23</td></tr><tr><td align="center" valign="middle">NSC77131</td><td align="center" valign="middle">99</td><td align="center" valign="middle">99</td><td align="center" valign="middle">9</td><td align="center" valign="middle">52</td></tr><tr><td align="center" valign="middle">NSC400718</td><td align="center" valign="middle">89</td><td align="center" valign="middle">88</td><td align="center" valign="middle">38</td><td align="center" valign="middle">23</td></tr><tr><td align="center" valign="middle">NSC34443</td><td align="center" valign="middle">86</td><td align="center" valign="middle">81</td><td align="center" valign="middle">57</td><td align="center" valign="middle">-7</td></tr><tr><td align="center" valign="middle">NSC630814</td><td align="center" valign="middle">84</td><td align="center" valign="middle">82</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">75</td></tr><tr><td align="center" valign="middle">NSC102798</td><td align="center" valign="middle">77</td><td align="center" valign="middle">74</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">61</td></tr><tr><td align="center" valign="middle">NSC4348</td><td align="center" valign="middle">73</td><td align="center" valign="middle">61</td><td align="center" valign="middle">34</td><td align="center" valign="middle">9</td></tr><tr><td align="center" valign="middle">NSC400937</td><td align="center" valign="middle">73</td><td align="center" valign="middle">66</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">70</td></tr><tr><td align="center" valign="middle">NSC4624</td><td align="center" valign="middle">65</td><td align="center" valign="middle">47</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">49</td></tr><tr><td align="center" valign="middle">NSC2269</td><td align="center" valign="middle">64</td><td align="center" valign="middle">60</td><td align="center" valign="middle">27</td><td align="center" valign="middle">1</td></tr><tr><td align="center" valign="middle">NSC255523</td><td align="center" valign="middle">59</td><td align="center" valign="middle">33</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">-7</td></tr><tr><td align="center" valign="middle">NSC670682</td><td align="center" valign="middle">50</td><td align="center" valign="middle">54</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">43</td></tr><tr><td align="center" valign="middle">NSC99790</td><td align="center" valign="middle">46</td><td align="center" valign="middle">36</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">33</td></tr><tr><td align="center" valign="middle">NSC646375</td><td align="center" valign="middle">26</td><td align="center" valign="middle">20</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">1</td></tr><tr><td align="center" valign="middle">NSC27605</td><td align="center" valign="middle">26</td><td align="center" valign="middle">10</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">2</td></tr><tr><td align="center" valign="middle">NSC107661</td><td align="center" valign="middle">18</td><td align="center" valign="middle">7</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">-2</td></tr><tr><td align="center" valign="middle">NSC293892</td><td align="center" valign="middle">15</td><td align="center" valign="middle">3</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">-5</td></tr><tr><td align="center" valign="middle">NSC44037</td><td align="center" valign="middle">15</td><td align="center" valign="middle">9</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">8</td></tr><tr><td align="center" valign="middle">NSC77680</td><td align="center" valign="middle">13</td><td align="center" valign="middle">7</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">21</td></tr><tr><td align="center" valign="middle">NSC80136</td><td align="center" valign="middle">13</td><td align="center" valign="middle">2</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">-3</td></tr><tr><td align="center" valign="middle">NSC114010</td><td align="center" valign="middle">11</td><td align="center" valign="middle">-3</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">-2</td></tr><tr><td align="center" valign="middle">NSC268226</td><td align="center" valign="middle">9</td><td align="center" valign="middle">0</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">3</td></tr><tr><td align="center" valign="middle">NSC163444</td><td align="center" valign="middle">9</td><td align="center" valign="middle">5</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">2</td></tr><tr><td align="center" valign="middle">NSC377438</td><td align="center" valign="middle">8</td><td align="center" valign="middle">-3</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">17</td></tr><tr><td align="center" valign="middle">NSC131119</td><td align="center" valign="middle">8</td><td align="center" valign="middle">0</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">14</td></tr><tr><td align="center" valign="middle">NSC39302</td><td align="center" valign="middle">7</td><td align="center" valign="middle">-2</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">12</td></tr><tr><td align="center" valign="middle">NSC317609</td><td align="center" valign="middle">7</td><td align="center" valign="middle">1</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">8</td></tr><tr><td align="center" valign="middle">NSC232469</td><td align="center" valign="middle">7</td><td align="center" valign="middle">-7</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">-4</td></tr><tr><td align="center" valign="middle">NSC655184</td><td align="center" valign="middle">7</td><td align="center" valign="middle">-11</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">5</td></tr><tr><td align="center" valign="middle">NSC92432</td><td align="center" valign="middle">6</td><td align="center" valign="middle">-1</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">8</td></tr><tr><td align="center" valign="middle">NSC137050</td><td align="center" valign="middle">6</td><td align="center" valign="middle">-1</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">3</td></tr><tr><td align="center" valign="middle">NSC158437</td><td align="center" valign="middle">5</td><td align="center" valign="middle">1</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">15</td></tr><tr><td align="center" valign="middle">NSC613624</td><td align="center" valign="middle">4</td><td align="center" valign="middle">-1</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">6</td></tr><tr><td align="center" valign="middle">NSC60360</td><td align="center" valign="middle">4</td><td align="center" valign="middle">-4</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">10</td></tr><tr><td align="center" valign="middle">NSC330685</td><td align="center" valign="middle">4</td><td align="center" valign="middle">2</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">1</td></tr><tr><td align="center" valign="middle">NSC54251</td><td align="center" valign="middle">4</td><td align="center" valign="middle">-4</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">-1</td></tr><tr><td align="center" valign="middle">NSC313453</td><td align="center" valign="middle">3</td><td align="center" valign="middle">-5</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">5</td></tr><tr><td align="center" valign="middle">NSC132916</td><td align="center" valign="middle">-1</td><td align="center" valign="middle">-3</td><td align="center" valign="middle">ND</td><td align="center" valign="middle">3</td></tr></tbody></table></table-wrap></floats-group></article>